Document:

Form of Italian Indemnity Agreement

 Exhibit 10.1 
 INDEMNITY AGREEMENT 
 THIS INDEMNITY AGREEMENT
(this “Agreement”) is made as of             , 2009 (the “Effective Date”), by and between Cell Therapeutics, Inc., a Washington corporation (the
“Company”), and                              (the “Indemnitee”), a
                             of the Company’s Italian branch located in Bresso (MI), Via Ariosto
23 (the “Italian Branch”). 
 THE PARTIES TO THIS AGREEMENT enter into this Agreement on the basis of the
following facts, intentions and understandings: 
 A. The Indemnitee is currently serving as an agent of the Company and
in such capacity renders valuable services to the Company. 
 B. The Company has investigated the availability and
sufficiency of liability insurance and Washington statutory indemnification provisions to provide its agents with adequate protection against various legal risks and potential liabilities to which agents are subject in connection with their position
with the Company and has concluded that insurance and statutory provisions may provide inadequate and unacceptable protection to certain individuals requested to serve as its agents. 
 C. In order to induce and encourage highly experienced and capable persons such as the Indemnitee to continue to serve as an agent of
the Company, the Board of Directors of the Company has determined, after due consideration and investigation of the terms and provisions of this Agreement and the various other options available to the Company and the Indemnitee in lieu of this
Agreement, that this Agreement is not only reasonable and prudent but necessary to promote and ensure the best interests of the Company and its shareholders. 
 NOW, THEREFORE, In consideration of the continued services of the Indemnitee and in order to induce the Indemnitee to continue to serve as an agent of the Company, the Company and the Indemnitee
agree as follows: 
 1. Definitions. As used in this Agreement: 
 1.1 A “Change in Control” shall be deemed to have occurred if (i) any “person” (as that term is used in
Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than any shareholder of the Company (and its affiliates) owning ten percent (10%) or more of the Company’s voting stock on
the date hereof, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power
represented by the Company’s then outstanding voting securities; provided, however, that unless otherwise determined in the specific case by a majority vote of the Board of Directors, a “Change in Control” shall not be
deemed to have occurred pursuant to this clause (i) if the beneficial owner is the Company, a subsidiary of the Company or an employee stock ownership plan or other employee benefit plan of the Company or a subsidiary of the Company, whether
such beneficial owner’s voting power is in excess of fifty percent (50%) or otherwise, or because the Company reports that a change in control of the Company has occurred or will occur in the future by reason of such beneficial ownership;
(ii) during any period of two consecutive

 
years, individuals who at the beginning of the two year period constitute the Board of Directors of the Company and any new director whose election by the Board of Directors or nomination for
election by the Company’s shareholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so
approved, cease for any reason to constitute a majority of the Board of Directors; (iii) the shareholders of the Company approve a merger or consolidation of the Company with any other corporation or other entity, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior to such a merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity) at least a majority of the total voting power represented by the voting securities of the Company or the surviving entity outstanding immediately after the merger or consolidation; or (iv) the shareholders of the Company
approve a plan of liquidation, dissolution or winding up of the Company or an agreement for the sale or disposition by the Company (in one transaction or a series of transactions) of all or substantially all the Company’s assets to another
corporation or other entity, and as a result of such sale or disposition, less than a majority of the combined voting power of the then outstanding voting securities of such other corporation or entity immediately after such sale or disposition is
held in the aggregate by the holders of voting stock of the Company immediately prior to such sale or disposition. 
 1.2
The term “Enterprise” shall include any corporation, partnership, joint venture, limited liability company, employee benefit plan or other enterprise. 
 1.3 The term “Expenses” includes, without limitation, attorneys’ fees, disbursements and retainers, accounting and witness fees, travel and deposition costs, expenses of
investigations, judicial or administrative proceedings or appeals, amounts paid in settlement by or on behalf of the Indemnitee, and any expenses of establishing a right to indemnification, pursuant to this Agreement or otherwise, including
reasonable compensation for time spent by the Indemnitee in connection with the investigation, defense or appeal of a Proceeding or action for indemnification for which the Indemnitee is not otherwise compensated by the Company or any third party.
The term “Expenses” does not include the amount of judgments, fines, penalties or ERISA excise taxes actually levied against the Indemnitee. 
 1.4 The term “fullest extent permitted by applicable law” shall mean the fullest extent authorized or permitted under applicable statutory or decisional law as amended or interpreted from
time to time. 
 1.5 The term “Indemnified Costs” means all Expenses, judgments, fines, penalties and ERISA
excise taxes actually and reasonably incurred by the Indemnitee in connection with the investigation, defense, appeal or settlement of any Proceeding. 
 1.6 A “Potential Change in Control” shall be deemed to have occurred if (i) the Company enters into an agreement or arrangement, the consummation of which would result in the
occurrence of a Change in Control; (ii) any person (including the Company) publicly announces an intention to take or to consider taking actions which if consummated would constitute a Change in Control; (iii) any person (other than a
trustee or other fiduciary holding securities under an employee benefit plan of the Company acting in such capacity or a

  

 2 

 
corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company), who is or becomes the beneficial
owner, directly or indirectly, of securities of the Company representing ten percent (10%) or more of the combined voting power of the Company’s then outstanding voting securities increases such person’s beneficial ownership of the
securities by five percent (5%) or more over the percentage so owned by that person on the date this Agreement is executed; or (iv) the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in
Control has occurred. 
 1.7 The term “Proceeding” shall include any threatened, pending or completed action,
suit or proceeding (including in each case appeals thereof), whether brought by or in the name of the Company or otherwise, whether of a civil, criminal, administrative, investigative or other nature, whether formal or informal, and whether or not
the Indemnitee is or was an officer, employee, agent or fiduciary of the Company, or is or was serving at the request of the Company as an officer, employee, agent, partner, member, trustee or fiduciary of another Enterprise at the time any
liability or Expense is incurred for which indemnification or reimbursement is to be provided under this Agreement. For the avoidance of doubt, the term “Proceeding” shall include any Health and Safety Proceedings, as defined in subsection
8.2. 
 2. Indemnification. 
 2.1 Indemnification in Third Party Actions. The Company shall indemnify the Indemnitee in accordance with the provisions of this subsection 2.1 if the Indemnitee is a party to or threatened
to be made a party to or otherwise involved in any manner (including, without limitation, involvement as a non-party witness) in any Proceeding (other than a Proceeding by or in the name of the Company to procure a judgment in its favor), by reason
of the fact that the Indemnitee is or was an officer, employee, agent or fiduciary of the Company, or is or was serving at the request of the Company as an officer, employee, agent, partner, member, trustee or fiduciary of another Enterprise,
against all Expenses, judgments, fines, penalties and ERISA excise tax actually and reasonably incurred by the Indemnitee in connection with the Proceeding, to the fullest extent permitted by applicable law; provided that any
settlement be approved in writing by the Company, which approval shall not be unreasonably withheld or delayed or applied in an inconsistent manner. 
 2.2 Indemnification in Proceedings by or in the Name of the Company. The Company shall indemnify the Indemnitee in accordance with the provisions of this subsection 2.2 if the Indemnitee is
a party to or threatened to be made a party to or otherwise involved in any manner (including, without limitation, involvement as a non-party witness) in any Proceeding by or in the name of the Company to procure a judgment in its favor by reason of
the fact that the Indemnitee was or is an officer, employee, agent or fiduciary of the Company, or is or was serving at the request of the Company as an officer, employee, agent, partner, member, trustee or fiduciary of another Enterprise, against
all Expenses actually and reasonably incurred by the Indemnitee in connection with the Proceeding, to the fullest extent permitted by applicable law. 
  

 3 

 2.3 Partial Indemnification. If the Indemnitee is entitled under any provision
of this Agreement to indemnification by the Company for some or a portion of, but not the total amount of, the Expenses, judgments, fines, penalties or ERISA excise taxes actually and reasonably incurred by the Indemnitee in the investigation,
defense, appeal or settlement of any Proceeding or otherwise in connection with any Proceeding, the Company shall indemnify the Indemnitee for the portion of the Expenses, judgments, fines, penalties or ERISA excise taxes to which the Indemnitee is
entitled. 
 2.4 Indemnification Hereunder Not Exclusive. The indemnification provided by this Agreement shall not
be deemed exclusive of, and shall be in addition to, any indemnification or other rights to which the Indemnitee may be entitled under the charter of the Company, as the same may be amended from time to time (the “Charter”), the bylaws of
the Company, as the same may be amended from time to time (the “Bylaws”), any agreement, any vote of shareholders or disinterested directors, applicable law, or otherwise, both as to action in the Indemnitee’s official capacity and as
to action in another capacity on behalf of the Company while holding office; provided, however, that to the extent the Indemnitee otherwise would have any greater right to indemnification under any provision of the Charter or Bylaws as
in effect on the Effective Date, the Indemnitee shall be deemed to have such greater right hereunder; provided, further, that to the extent there are any changes made to the Charter and/or Bylaws which permit a greater right to
indemnification than that provided under this Agreement, the Indemnitee shall be entitled to have such greater right. The Company shall not adopt any amendment to the Charter or Bylaws, the effect of which (intended or otherwise) would be to deny,
diminish or encumber the Indemnitee’s right to indemnification under the Charter, Bylaws, applicable law or otherwise as applied to any act or failure to act occurring in whole or in part prior to the date upon which the amendment was approved
by the Board of Directors of the Company and/or its shareholders, as the case may be. 
 2.5 Indemnification of
Expenses of Successful Party. Notwithstanding any other provisions of this Agreement, to the extent that the Indemnitee has been successful in defense of any Proceeding or in defense of any claim, issue or matter in the Proceeding, on the merits
or otherwise, including the dismissal of a Proceeding without prejudice, the Indemnitee shall be indemnified against all reasonable Expenses incurred in connection therewith to the fullest extent permitted by applicable law. 
 2.6 Indemnification of Expenses Incurred in Connection with a Proceeding. The Indemnitee’s Expenses incurred in
connection with any Proceeding concerning the Indemnitee’s right to indemnification or advances in whole or in part pursuant to this Agreement, the Charter or the Bylaws shall also be indemnified by the Company regardless of the outcome of the
Proceeding, unless a court of competent jurisdiction determines that each of the material assertions made by the Indemnitee in the Proceeding was not made in good faith or was frivolous. 
 3. Presumptions. 
 3.1 Presumption Regarding Standard of Conduct. The Indemnitee shall be conclusively presumed to have met the relevant standards of conduct as defined by applicable law for
indemnification pursuant to this Agreement, unless a determination that the Indemnitee has not met the relevant standards is made by (i) a majority vote of a quorum of the directors of the Company who are not parties to the Proceeding, and if a
quorum cannot be obtained, a

  

 4 

 
majority vote of a committee duly designated by the directors of the Company, consisting solely of two or more directors who are not parties to the Proceeding, (ii) special legal counsel
selected by the directors or its committee in the manner prescribed in clause (i) above, or selected by a majority vote of all of the directors of the Company, or (iii) the shareholders of the Company, provided that those shares owned or
voted under the control of directors who are at the time parties to the Proceeding may not vote. 
 3.2 Determination
of Right to Indemnification. If a claim under this Agreement is not paid by the Company within thirty (30) days of receipt of written notice, the right to indemnification as provided by this Agreement shall be enforceable by the Indemnitee
in any court of competent jurisdiction. The burden of proving by clear and convincing evidence that indemnification or advances are not appropriate shall be on the Company. Neither the failure of the directors or shareholders of the Company or
special legal counsel to have made a determination prior to the commencement of the action that indemnification or advances are proper in the circumstances because the Indemnitee has met the applicable standard of conduct, nor an actual
determination by the directors or shareholders of the Company or special legal counsel that the Indemnitee has not met the applicable standard of conduct, shall be a defense to the action or create a presumption that the Indemnitee has not met the
applicable standard of conduct. In addition, the termination of a Proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent shall not, of itself, be determinative that the Indemnitee has not met the
applicable standard of conduct. 
 4. Expenses. 
 4.1 Advances of Expenses. The reasonable Expenses incurred by the Indemnitee in any Proceeding shall be paid promptly by the
Company in advance of the final disposition of the Proceeding at the written request of the Indemnitee, accompanied by documentation substantiating such request, including a written affirmation of the Indemnitee’s good faith belief that the
Indemnitee has met the applicable standard of conduct, to the fullest extent permitted by applicable law (but only to the extent permissible under Section 402 of the Sarbanes-Oxley Act of 2002, as may be amended from time to time) and without
requiring any preliminary determination of the ultimate entitlement of the Indemnitee to indemnification, provided that the Indemnitee shall also undertake in writing to repay the amount advanced to the extent that it is ultimately determined that
the Indemnitee did not meet the applicable standard of conduct or is otherwise not entitled to indemnification. 
 4.2
Subrogation. If the Company pays Indemnified Costs, the Company will be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee against third parties. The Indemnitee will do all things reasonably necessary
to secure such rights, including the execution of documents necessary to enable the Company effectively to bring suit to enforce such rights. 
 5. Change in Control. 
 5.1 Determination of Rights.
Subject to subsection 5.2 of this Agreement, the Company agrees that if there is a Potential Change in Control of the Company (other than in connection with a Change in Control which has been approved by a majority of the Company’s

  

 5 

 
Board of Directors who were directors immediately prior to the Change in Control) then with respect to all matters thereafter arising concerning the rights of the Indemnitee to indemnity payments
and Expense advances under this Agreement or any other agreement, the Charter or Bylaws in effect relating to claims for indemnifiable events, the Company shall seek legal advice only from independent counsel selected by the Indemnitee and approved
by the Company (which approval shall not be unreasonably withheld), and who has not otherwise performed services for the Company or the Indemnitee within the last five (5) years (other than in connection with such matters) (“Special
Independent Counsel”). The Special Independent Counsel, among other things, shall render its written opinion to the Company and the Indemnitee as to whether and to what extent the Indemnitee would be permitted to be indemnified under applicable
law. The Company agrees to pay the reasonable fees of the Special Independent Counsel referred to above and may fully indemnify the Special Independent Counsel against any and all expenses (including, without limitation, attorneys’ fees),
claims, liabilities and damages arising out of or relating to this Agreement. 
 5.2 Merger or Consolidation. In
the event that the Company shall be a constituent corporation in a merger, consolidation or other reorganization, the Company shall require as a condition thereto, (a) if the Company is not the surviving, resulting or acquiring corporation
therein, that the surviving, resulting or acquiring corporation agree to indemnify Indemnitee to the full extent provided herein, and (b) whether or not the Company is the surviving, resulting or acquiring corporation therein, that Indemnitee
shall stand in the same position under this Agreement with respect to the surviving, resulting or acquiring corporation as Indemnitee would have with respect to the Company if its separate existence had continued. 
 6. Indemnification Procedure. 
 6.1 Notice. Promptly after receipt by the Indemnitee of notice of the commencement of any Proceeding or notice of the Indemnitee’s involvement in any Proceeding, if later, the
Indemnitee will, if a claim is to be made against the Company under this Agreement, notify the Company of the commencement of the Proceeding, or the Indemnitee’s involvement in such Proceeding, as applicable. The failure to notify the Company
will not relieve it from any liability which it may have to the Indemnitee otherwise than under this Agreement. 
 6.2
Company Participation. With respect to any Proceeding for, or with respect to, which indemnification is requested, the Company will be entitled to participate in the Proceeding at its own expense and, except as otherwise provided below,
to the extent that it may wish, the Company may assume the defense of the Proceeding, with counsel satisfactory to the Indemnitee. After notice from the Company to the Indemnitee of its election to assume the defense of a Proceeding, during the
Company’s good faith active defense the Company will not be liable to the Indemnitee under this Agreement for any legal or other expenses subsequently incurred by the Indemnitee in connection with the defense of the Proceeding, other than
reasonable costs of investigation or as otherwise provided below. The Company shall not settle any Proceeding in any manner which would impose any penalty or limitation on the Indemnitee without the Indemnitee’s written consent. The Indemnitee
shall have the right to employ the Indemnitee’s counsel in any Proceeding but the fees and expenses of the counsel incurred after notice from the Company of its assumption of the defense of the Proceeding shall be at the expense of the
Indemnitee, unless (i) the employment of counsel by the Indemnitee has been

  

 6 

 
authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense
of a Proceeding, or (iii) the Company shall not in fact have employed counsel to assume the defense of a Proceeding, in each of which cases the fees and expenses of the Indemnitee’s counsel shall be at the expense of the Company. The
Company shall not be entitled to assume the defense of any Proceeding brought by or on behalf of the Company or as to which the Indemnitee has made the conclusion that there may be a conflict of interest between the Company and the Indemnitee.

 7. Limitations on Indemnification. No payments pursuant to this Agreement shall be made by the Company:

 (a) to indemnify or advance Expenses to the Indemnitee with respect to Proceedings initiated or brought voluntarily by the
Indemnitee and not by way of defense, unless the Proceedings are brought to establish or enforce a right to indemnification under this Agreement, the Charter or Bylaws or any other statute or law or otherwise as required under applicable law, and
provided that the indemnification or advancement of Expenses may be provided by the Company in specific cases if the Board of Directors finds it to be appropriate; 
 (b) to indemnify the Indemnitee for any Expenses, judgments, fines, penalties or ERISA excise taxes for which payment is actually made to the Indemnitee under a valid and collectible insurance policy,
except in respect of any excess beyond the amount of payment under the insurance; 
 (c) to indemnify the Indemnitee for any
Expenses, judgments, fines or penalties sustained in any Proceeding for an accounting of profits made from the purchase or sale by the Indemnitee of securities of the Company pursuant to the provisions of Section 16(b) of the Securities
Exchange Act of 1934, the rules and regulations promulgated thereunder and amendments thereto or similar provisions of any federal, state or local statutory law; 
 (d) to indemnify the Indemnitee in connection with a proceeding by or in the right of the Company in which the Indemnitee is adjudged though a proceeding, which may include alternative dispute resolution,
to be liable to the Company; 
 (e) to indemnify the Indemnitee in connection with a proceeding by a third party charging
improper personal benefit to the Indemnitee, whether or not involving action in the Indemnitee’s official capacity, in which the Indemnitee is adjudged though a proceeding, which may include alternative dispute resolution, to be liable on the
basis that personal benefit was improperly received by the Indemnitee; 
 (f) to indemnify the Indemnitee from or on account of
acts or omissions of the Indemnitee finally adjudged though a proceeding, which may include alternative dispute resolution, to be intentional misconduct or a knowing violation of law, or any transaction with respect to which it is finally adjudged
though a proceeding, which may include alternative dispute resolution, that the Indemnitee personally received a benefit of money, property or services to which the Indemnitee was not legally entitled; or 
  

 7 

 (g) if a court of competent jurisdiction shall finally determine that any indemnification
hereunder is unlawful. 
 8. Duration of Agreement. 
 8.1 Except as specifically provided in subsection 8.2 of this Agreement, this Agreement shall continue until and terminate upon the
later to occur of: (a) ten (10) years after the date that the Indemnitee shall have ceased to serve as an agent of the Company in the capacity described above and (b) one (1) year after the final termination of any Proceeding
then pending in respect of which the Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to subsection 3.2 of this Agreement relating thereto. 
 8.2 Notwithstanding subsection 8.1 of this Agreement, in the case of a Proceeding brought by a current or former employee, or his or
her estate, that arises from or is in any way related to issues of such employee’s health and safety while working at the Italian Branch, including, without limitation, physical damages or professional diseases due to the employee’s
extended exposure to chemical, biological or radioactive substances and/or other hazardous materials (any such Proceeding, a “Health and Safety Proceeding”), this Agreement shall continue until and terminate upon the later to occur of:
(a) twenty five (25) years after the date that the Indemnitee shall have ceased to serve as an agent of the Company in the capacity described above and (b) one (1) year after the final termination of any Health and Safety
Proceeding then pending in respect of which the Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to subsection 3.2 of this Agreement relating thereto.

 9. Miscellaneous. 
 9.1 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Indemnitee and the Indemnitee’s spouse, heirs, personal representatives and
assigns, and the Company and its successors and assigns. Nothing in this Agreement is intended to confer any rights or remedies upon any other person. 
 9.2 Separability. Each provision of this Agreement is a separate and distinct agreement and independent of the others, so that if any provision of this Agreement shall be held to be
invalid or unenforceable for any reason, the invalidity or unenforceability shall not affect the validity or enforceability of the other provisions of this Agreement. To the extent required, any provision of this Agreement may be modified by a court
of competent jurisdiction to preserve its validity and to provide the Indemnitee with the broadest possible indemnification permitted under applicable law. 
 9.3 Savings Clause. If this Agreement or any portion of it is invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify the
Indemnitee as to Expenses, judgments, fines, penalties or ERISA excise taxes with respect to any Proceeding to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated or by any other applicable law.

  

 8 

 9.4 Interpretation; Governing Law. This Agreement shall be construed as
a whole and in accordance with its fair meaning. Headings are for convenience only and shall not be used in construing meaning. This Agreement shall be governed and interpreted in accordance with the laws of the State of Washington. 
 9.5 Amendments. No amendment, waiver, modification, termination or cancellation of this Agreement shall be effective
unless in writing signed by the party against whom enforcement is sought. The indemnification rights afforded to the Indemnitee by this Agreement are contract rights and may not be diminished, eliminated or otherwise affected by amendments to the
Charter, Bylaws or agreements including D&O Insurance policies. 
 9.6 Counterparts. This Agreement may
be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each party and delivered to the other. 
 9.7 Notices. Any notice required to be given under this Agreement shall be directed to the Company at 501 Elliott
Avenue, Suite 400, Seattle, Washington 98119, Attention: General Counsel, with a copy to C. Brophy Christensen, Two Embarcadero Center, 28th Floor, San Francisco, California 94111, and to the Indemnitee at the address set forth below or to
another address as either shall designate in writing. 
 [Signature Page Follows] 
  

 9 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above. 
  

			
	“Indemnitee”
	
	  

	Name:	 	
	
	Notice Address:
	
	  

	  

	
	“Company”
	
	 CELL THERAPEUTICS, INC.
 a Washington corporation

		
	By:	 	  

	Name:	 	
	Title:	 	

  

 S-1Series B Preferred Stock Purchase Agreement

 Exhibit 10.1 
 SERIES B PREFERRED STOCK PURCHASE AGREEMENT 
 THIS
SERIES B PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of December 14, 2009, by and between Purple Communications, Inc., a Delaware corporation (the “Company”), and the investors listed on
Schedule A hereto (each, an “Investor” and collectively, the “Investors”). 
 THE PARTIES
HEREBY AGREE AS FOLLOWS: 
 1. Purchase and Sale of Stock. 
 1.1 Sale and Issuance of Series B Preferred Stock. 
 (a) The Board of Directors of the Company has approved and shall file with the Secretary of State of the State of Delaware on or before the Closing (as defined below), a Certificate of Designations,
Preferences and Rights of Series B Preferred Stock in the form attached hereto as Exhibit A-1 (the “Certificate of Designations”). 
 (b) The Board of Directors of the Company has authorized, subject to the receipt of all necessary stockholder approvals and the filing of the Certificate of Amendment (as defined below), (i) the sale
and issuance to the Investors of the Series B Preferred Stock (as defined below), (ii) the issuance of the shares of Common Stock (as defined below) to be issued upon conversion of the Series B Preferred Stock (the “Conversion
Shares”), (iii) the sale and issuance to the Investors of the Warrants (as defined below), and (iv) the issuance of the shares of Common to be issued upon exercise of the Warrants (the “Warrant Shares”). The
Series B Preferred Stock, the Conversion Shares and the Warrant Shares shall have the rights, preferences, privileges and restrictions set forth in the Certificate of Designations or the Fourth Amended and Restated Certificate of Incorporation of
the Company, as applicable. 
 (c) Subject to the terms and conditions of this Agreement, each Investor agrees, severally and
not jointly, to purchase at the Closing (as defined below) and the Company agrees to sell and issue to each Investor at the Closing, that number of shares of the Company’s Series B Preferred Stock set forth opposite each Investor’s name on
Part I of Schedule A hereto for a purchase price of $1.50 per share (the “Per Share Price”). 
 (d) Subject to
the terms and conditions of this Agreement, each Investor agrees, severally and not jointly, to purchase at the Subsequent Closing (as defined below) and the Company agrees to sell and issue to each Investor at the Subsequent Closing, that number of
shares of the Company’s Series B Preferred Stock set forth opposite each Investor’s name on Part II of Schedule A hereto for a purchase price of the Per Share Price. 
 1.2 Closing and Subsequent Closing. Assuming that all other conditions of Closing have been satisfied or waived, the purchase and
sale of the Series B Preferred Stock to be sold at the Closing pursuant to Section 1.1(c) shall take place at the offices of Stradling Yocca Carlson & Rauth, 660 Newport Center Drive, Suite 1600, Newport Beach, CA 92660 at 10:00 am on
December 14, 2009 or at such other time and place as the Company and Investors acquiring in the aggregate more than half of the shares of Series B Preferred Stock sold pursuant hereto mutually agree upon orally or in writing (which time and
place are designated as the “Closing”). At the Closing, the Company shall deliver to each Investor a certificate representing the Series B Preferred Stock that such Investor is purchasing against payment of the purchase price
therefor by wire transfer of immediately available funds to an account designated by the Company. 
  

 1 

 Assuming that all conditions of the Subsequent Closing have been satisfied or waived, the
purchase and sale of the Series B Preferred Stock to take place at the Subsequent Closing shall take place at the offices of Stradling Yocca Carlson & Rauth, 660 Newport Center Drive, Suite 1600, Newport Beach, CA 92660 at 10:00 am on
December 18, 2009 or at such other time and place as the Company and Investors acquiring in the aggregate more than half of the shares of Series B Preferred Stock sold pursuant hereto mutually agree upon orally or in writing (which time and
place are designated as the “Subsequent Closing”). At the Subsequent Closing, the Company shall deliver to each Investor a certificate representing the Series B Preferred Stock that such Investor is purchasing at the Subsequent
Closing against payment of the purchase price therefor by wire transfer of immediately available funds to an account designated by the Company. 
 1.3 Use of Proceeds. The Company shall use the proceeds from the sale of the Series B Preferred Stock to the Investors (a) to pay all fees and expenses incurred in connection with the issuance
of the Series B Preferred Stock (including, without limitation, the fees and expenses of the Investors) and (b) for general working capital purposes. 
 1.4 Warrants. Concurrently with the Closing and, as applicable, the Subsequent Closing, the Company shall issue to each Investor a warrant (a “Warrant”) to purchase two
(2) shares of Common Stock of the Company for each share of Common Stock into which the Series B Preferred Stock purchased by such Investor hereunder is initially convertible. The Warrant shall be in the form of agreement attached hereto as
Exhibit A-3. 
 2. Representations and Warranties of the Company. The Company hereby represents and warrants to
each Investor that, except as set forth in the SEC Reports (as defined below) or in the Disclosure Letter (the “Disclosure Letter”) furnished to each Investor prior to execution hereof, which exceptions shall be deemed to be
representations and warranties as if made hereunder: 
 2.1 Organization, Good Standing and Qualification. The Company is
a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would
have a material adverse change in the assets, liabilities, customer or supplier relationships, financial condition, operations or results of operations of the Company taken as a whole, provided, however, in each case, not including any change that
(A) is generally applicable to the U.S. economy, (B) is generally applicable to Internet protocol data and voice providers, (C) results from the execution of this Agreement, the announcement of this Agreement or the consummation of
the transactions contemplated by this Agreement or (D) relates to changes in generally accepted accounting principles generally applicable to companies serving as Internet protocol data and voice providers occurring after the date of this
Agreement (a “Material Adverse Effect”). 
  

 2 

 2.2 Capitalization and Voting Rights. 
 (a) Authorized Stock. The authorized capital of the Company consists of: 
 (i) Preferred Stock. 11,671,180 shares of Preferred Stock, par value $.01 per share (the “Preferred Stock”),
7,736,944 of which are designated as Series A Preferred Stock, all of which are issued and outstanding as of the date hereof. Upon filing the Certificate of Designations with the Secretary of State of the State of Delaware, 3,333,333 shares of
Preferred Stock shall be designated Series B Preferred Stock, all of which may be sold pursuant to this Agreement. As of the date of the Subsequent Closing, the only shares of Series B Preferred Stock issued and outstanding are the shares issued to
the Investors pursuant hereto on the date of the Closing. 
 (ii) Common Stock. 50,000,000 shares of Common Stock, par
value $.01 per share (“Common Stock”), of which 9,218,542 shares are issued and outstanding as of the date hereof. 
 (b) Valid Issuance. The outstanding shares of Common Stock are all duly and validly authorized and issued, fully paid and nonassessable, and were issued in compliance with all applicable state and federal laws concerning the issuance
of securities. 
 (c) Rights to Acquire. Except for (i) options to purchase an aggregate of 2,252,351 shares of
Common Stock granted and outstanding under the Purple Relay Services Co.. 1999 Stock Option Plan, the Purple Communications, Inc. 1999 Stock Plan, the Purple Communications, Inc. Employee Stock Purchase Plan and the Purple Communications, Inc. 2005
Equity Compensation Plan (collectively, the “Company Option Plans”), and (ii) the Warrants, there are not outstanding any options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or
acquisition from the Company of any shares of its capital stock as of the date hereof. The Company has reserved a total of 3,409,055 shares of Common Stock for issuance under the Company Option Plans (including the shares described above).

 (d) Voting of Shares. Other than the Amended and Restated Investor Rights Agreement dated January 10, 2008
between the Company and the investors named therein (the “Investor Rights Agreement”), the Company is not a party or subject to any agreement or understanding and, to the Company’s knowledge, there is no agreement or
understanding between any persons and/or entities which affects or relates to the voting or giving of written consents with respect to any security of the Company. 
 2.3 Operating Subsidiaries. 
 (a) Schedule B hereto sets forth the name of
each operating subsidiary of the Company (each, an “Operating Subsidiary” and collectively, the “Operating Subsidiaries”) and the jurisdiction in which such Operating Subsidiary is incorporated. Each Operating
Subsidiary is a duly organized and validly existing corporation or other entity and has all requisite corporate power and authority to carry on its business as now conducted. Each Operating Subsidiary is duly qualified to transact business and is in
good standing in each jurisdiction in which the failure so to qualify would have a Material Adverse Effect. 
 (b) All of the
outstanding shares of capital stock of each Operating Subsidiary of the Company are duly and validly authorized and issued, fully paid and non-assessable and are owned directly by the Company, free and clear of all liens, encumbrances, preemptive
rights, subscription rights, other rights to purchase, voting or transfer restrictions and other claims, except as set forth in or contemplated by the First Lien Credit Agreement and the Second Lien Credit Agreement. There are no outstanding rights,
warrants or options to acquire, or instruments convertible into or exchangeable for, any equity interests of any Operating Subsidiary. 
  

 3 

 Each subsidiary of the Company that is not an Operating Subsidiary (i) has consolidated
gross revenues for the period of four fiscal consecutive quarters most recently ended of less than $5,000, (ii) has consolidated total assets on the last day of the fiscal quarter most recently ended of less than $5,000 and (iii) does not
own or possess the right to use any Intellectual Property Rights or other assets that are material to the business of the Company and its subsidiaries, taken as a whole. For purposes of this Agreement, the terms “subsidiary” and
“subsidiaries” of any person means any corporation, partnership, joint venture, limited liability company, association or other legal entity of which such person (either alone or through or together with any other subsidiary), owns,
directly or indirectly, 50% or more of the stock or other equity interests the holder of which is generally entitled to vote for the election of the board of directors or other governing body of such corporation, partnership, joint venture, limited
liability company, association or other legal entity. 
 2.4 Authorization. Other than the completion of the Information
Statement Process, the filing of the Certificate of Designations and the Certificate of Amendment with the Secretary of State of the State of Delaware and filings required under federal and state securities laws, all corporate action on the part of
the Company, its directors and stockholders necessary for the authorization, execution and delivery by the Company of this Agreement and the Warrants, the performance of all obligations of the Company hereunder and thereunder, and the authorization,
sale, issuance and delivery of the Series B Preferred Stock and Warrants being sold hereunder, the Conversion Shares issuable upon conversion of the Series B Preferred Stock and the Warrant Shares issuable upon exercise of the Warrants has been
taken or will be taken prior to the Closing or, in respect of the Series B Preferred Stock, Warrants, Conversion Shares and Warrant Shares to be issued or issuable at the Subsequent Closing, the Subsequent Closing. This Agreement and, when executed,
the Warrants, constitute valid and legally binding obligations of the Company, enforceable in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of
general application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 2.5 Valid Issuance of Preferred Stock. Other than the completion of the Information Statement Process, the filing of the Certificate
of Designations and the Certificate of Amendment with the Secretary of State of the State of Delaware, (A) the Series B Preferred Stock that is being purchased by the Investors hereunder, when issued, sold and delivered in accordance with the
terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer (a) under this Agreement and the
Investor Rights Agreement, if applicable, (b) under applicable state and federal securities laws and (c) otherwise imposed as a result of actions taken by the Investors; and (B) the Conversion Shares and Warrant Shares have been duly
and validly reserved for issuance and, upon issuance in accordance with the terms of the Restated Certificate of Incorporation of the Company, as amended by the Certificate of Amendment, will be duly and validly issued, fully paid and nonassessable
and will be free of restrictions on transfer, other than restrictions on transfer (a) under this Agreement and the Investor Rights Agreement, if applicable, (b) under applicable state and federal securities laws and (c) otherwise
imposed as a result of actions taken by the Investors. 
  

 4 

 2.6 Governmental Consents. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement,
except for (i) such consents, approvals, orders, authorizations, registrations, qualifications, designations, declarations or filings which are not required to be obtained prior to the Closing and such consents, approvals, orders,
authorizations, registrations, qualifications, designations, declarations or filings which are not required to be obtained prior to the Subsequent Closing, (ii) the filing of the Certificate of Designations and the Certificate of Amendment with
the Secretary of State of the State of Delaware, and (iii) such filings as are required pursuant to applicable federal and state securities laws and blue sky laws, which filings will be effected within the required statutory period. 

2.7 Offering. Subject in part to the truth and accuracy of each Investor’s representations set forth in Section 3 of
this Agreement, the offer, sale and issuance of the Series B Preferred Stock, the Warrants, the Conversion Shares and the Warrant Shares as contemplated by this Agreement are exempt from the registration requirements of the Securities Act of 1933,
as amended (the “Act”), and the qualification or registration requirements of applicable state blue sky laws, as such registration requirements and laws currently exist. Neither the Company nor any authorized agent acting on its
behalf will take any action hereafter that would cause the loss of such exemption. 
 2.8 Litigation. There is no action,
suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened against the Company that questions the validity of this Agreement or the Warrants, or the right of the Company to enter into such agreements or to
consummate the transactions contemplated hereby, or that would reasonably be expected to result, either individually or in the aggregate, in a Material Adverse Effect or in any change in the current equity ownership of the Company. Neither the
Company nor any Operating Subsidiary is a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. 
 2.9 Intellectual Property. Except as would not have a Material Adverse Effect: 
 (a) To its knowledge, the Company and each Operating Subsidiary owns sufficient right, title and interest in and to, or has sufficient
right to use pursuant to a valid license, option, assignment or agreement, all of the Intellectual Property Rights (as defined below) used by them and which the Company believes are necessary for the operation of the business of the Company and each
Operating Subsidiary as presently conducted, and the lack of which would conflict with or infringe the rights of any third party, except for such items as have yet to be conceived or developed or that are expected to be available for licensing on
reasonable terms. The Company and each Operating Subsidiary has taken reasonable actions to maintain and protect the confidentiality of Intellectual Property Rights consisting of trade secrets that it owns. The Intellectual Property Rights that the
Company or any Operating Subsidiary owns, consisting of patents, copyrights, trademarks, service marks and trade names, do not, to the Company’s knowledge, conflict with or infringe upon the rights of third parties, except for such items as
have yet to be conceived or developed or that are expected to be available for licensing on reasonable terms. Since January 1, 2009, there have been no written claims made against the Company or any subsidiary asserting the invalidity, misuse
or unenforceability of any Intellectual Property Rights that the Company or any subsidiary owns and, to the Company’s knowledge, there are no valid grounds for the same. Since January 1, 2009, neither the Company nor any subsidiary has
received any communications alleging that the Company or any subsidiary has violated, infringed or

  

 5 

 
misappropriated any Intellectual Property Rights of any other person or entity. To the Company’s knowledge, neither the Company nor any subsidiary is violating, infringing or
misappropriating the Intellectual Property Rights of any other person or entity. Since January 1, 2009, to the Company’s knowledge, no third party has interfered with, infringed upon, violated, misappropriated, or otherwise come into
conflict with any of the Company’s or any of its Operating Subsidiary’s Intellectual Property Rights, or of any right of any third party (to the extent licensed by or through the Company or its Operating Subsidiaries), or breached any
license or agreement involving Intellectual Property Rights. Except as set forth on the Disclosure Letter, the Company has not brought any action, suit or proceeding or asserted any claim against any person or entity related to the foregoing. The
Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that
would interfere with the use of his or her best efforts to promote the interests of the Company or that would prevent the employee from assigning his/her inventions to the Company. 
 (b) Neither the execution nor delivery of this Agreement or the Warrants, nor the carrying on of the Company’s business by the
employees of the Company, nor the employment of any employee of the Company, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant
or instrument under which any of such employees is now obligated, including but not limited to, any employment contract, patent disclosure agreement, confidentiality agreement or any other contract or agreement relating to the relationship of any
such employee with the Company. 
 (c) For purposes of this Agreement, “Intellectual Property Rights” means
all (i) patents, patent applications, patent disclosures and inventions, (ii) trademarks, service marks, trade names, logos and corporate names and registrations and applications for registration thereof, (iii) copyrights (registered
and unregistered) and copyrightable works and registrations and applications for registration thereof, (iv) mask works and registrations and applications for registration thereof, (v) computer software, data, databases and documentation
thereof, (vi) trade secrets and other confidential information (including, without limitation, ideas, formulas, compositions, inventions (whether patentable or unpatentable and whether or not reduced to practice), know-how, manufacturing and
production processes and techniques, research and development information, drawings, specifications, designs, plans, proposals, technical data, financial and marketing plans and customer and supplier lists and information) and (vii) other
intellectual property rights. As used in this Agreement, the phrases “to the Company’s knowledge” and “the Company is not aware” or any similar expression or phrase refers to the actual knowledge of the
executive officers of the Company (and does not include any constructive or imputed notice of any information). 
 2.10
Compliance with Other Instruments. The Company is not in violation of any provision of its certificate of incorporation or Bylaws. Neither the Company nor any of its subsidiaries is in violation of any instrument, judgment, order, writ,
decree or contract, statute, rule or regulation to which the Company or any subsidiary is subject and a violation of which would reasonably be expected to result in a Material Adverse Effect. The execution, delivery and performance of this Agreement
and the Warrants, and the consummation of the transactions contemplated hereby and thereby will not result in any such violation, or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under
any such provision, instrument, judgment, order, writ, decree or contract or an event that results in the creation of any lien, charge or encumbrance upon any assets of the Company or any subsidiary or the

  

 6 

 
suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company or any subsidiary, their business or operations
or any of their assets or properties, other than conflicts, defaults or other results which would not reasonably be expected to result in a Material Adverse Effect. 
 2.11 Agreements; Action. 
 (a) Except for agreements explicitly
contemplated hereby, there are no agreements, written or oral, between the Company and any subsidiary and any of their officers, directors or affiliates. 
 (b) There are no agreements, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or decrees to which the Company or any subsidiary is a party or by which any of them is
bound that may involve the license of any Intellectual Property Rights or other proprietary right to or from the Company (other than licenses entered into in the ordinary course of business). 
 (c) There are no agreements, commitments, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or
decrees to which the Company or any subsidiary is a party or by which they are bound that may involve (i) obligations (contingent or otherwise), or payments to the Company or any subsidiary, in excess of $250,000, other than obligations of, or
payments to, the Company or any subsidiary arising from agreements entered into in the ordinary course of business, or (ii) provisions materially restricting the development, manufacture or distribution of the Company’s products or
services (collectively, “Material Contracts”). The Material Contracts are valid and in full force and effect as to the Company and any Operating Subsidiary, and, to the Company’s knowledge, to the other parties thereto.

 (d) With the exception of (i) indebtedness of the Company and its subsidiaries under that certain Credit Agreement
dated as of January 10, 2008, as amended from time to time (the “Second Lien Credit Agreement”) by and among the Company, Clearlake Capital Group, LP, as Administrative Agent and Collateral Agent and the Lenders party thereto,
and (ii) the indebtedness of the Company and its subsidiaries under that certain Credit Agreement dated as of January 10, 2008, as amended from time to time (the “First Lien Credit Agreement”) by and among the Company,
Churchill Financial LLC, as Administrative Agent and Ableco Finance LLC, as Collateral Agent (the First Lien Credit Agreement and the Second Lien Credit Agreement, collectively, the “Debt Financings”), neither the Company nor any
subsidiary has outstanding any indebtedness for money borrowed (which, for clarity, the parties agree does not include accounts payables or other trade payables, capital leases or accrued expenses) in excess of $250,000 or, in the case of
indebtedness for money borrowed individually less than $250,000, in excess of $5,000,000 in the aggregate, other than liabilities incurred in the ordinary course of business. 
 (e) For the purposes of subsections (a) and (b) above, all indebtedness, liabilities, agreements, understandings, instruments,
contracts and proposed transactions involving the same person or entity (including persons or entities the Company has reason to believe are affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts
of such subsections. 
 2.12 Related Party Transactions. Since the filing of the last SEC Report (as defined below),
there have been no related party transactions that would be required to be disclosed in the SEC Reports pursuant to Item 404(a) of the SEC’s Regulation S-K that have not been so disclosed in the SEC Reports. 
  

 7 

 2.13 SEC Filings; Financial Statements. 
 (a) Except for its Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, the Company has timely filed all reports and
proxy statements (including all information incorporated therein, amendments and supplements thereto) required to be filed by the Company with the Securities and Exchange Commission (the “SEC”) since January 1, 2009 (all
reports filed by the Company under the Securities Exchange Act of 1934, and the applicable rules and regulations promulgated thereunder since January 1, 2009, including any amendments thereto, collectively, the “SEC Reports”).
As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Exchange Act of 1934, and the applicable rules and regulations promulgated thereunder. As of the time of filing with the SEC,
none of the SEC Reports so filed contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. 
 (b) The audited consolidated financial statements of the Company (including any
related notes thereto) included in the SEC Reports (the “Year-End Statements”) have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods involved (except as
may be indicated in the notes thereto) and fairly present in all material respects the consolidated financial position of the Company and its subsidiaries at the respective dates thereof and the consolidated results of operations, cash flows and
changes in stockholders’ equity of the Company and its subsidiaries for the periods indicated. The unaudited consolidated financial statements of the Company (including any related notes thereto) for all interim periods included in the SEC
Reports (together with the Year-End Statements, the “Financial Statements”) have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods involved (except as may
be indicated in the notes thereto) and fairly present in all material respects the consolidated financial position of the Company and its subsidiaries at of the respective dates thereof and the consolidated results of operations, cash flows and
changes in stockholders’ equity of the Company and its subsidiaries for the periods indicated (subject to normal and recurring period-end adjustments that have not been and are not expected to be material to the Company and its subsidiaries
taken as a whole). 
 (c) To the Company’s knowledge, except as set forth in the Financial Statements or the Disclosure
Letter, the Company has no material liabilities, contingent or otherwise, other than (a) liabilities incurred in the ordinary course of business subsequent to June 30, 2009 and (b) liabilities or obligations under contracts and
commitments incurred in the ordinary course of business or otherwise not required under generally accepted accounting principles to be reflected in the Financial Statements. Except as disclosed in the Financial Statements, neither the Company nor
any subsidiary is a guarantor or indemnitor of any indebtedness of any other person, firm or corporation, other than the Company or any subsidiary. The Company maintains a system of accounting established and administered in accordance with
generally accepted accounting principles. 
 2.14 Changes. Since June 30, 2009, except as would not reasonably be
expected to have a Material Adverse Effect and except as contemplated by the transactions associated with the Operative Agreements and the Debt Financings, there has not been: 
 (a) any change in the assets, liabilities, financial condition or operating results of the Company and its subsidiaries, taken as a whole,
from that reflected in the Financial Statements, except changes in the ordinary course of business; 
  

 8 

 (b) any material change or amendment to a material contract or arrangement by which the
Company or any of its assets or properties is bound or subject; 
 (c) any sale, assignment, pledge, grant of security interest
or transfer of any patents, trademarks, copyrights, trade secrets or other intangible assets; 
 (d) any resignation or
termination of employment of any key employee of the Company and its Operating Subsidiaries; 
 (e) any mortgage, pledge,
transfer of a security interest in, or lien, created by the Company or any subsidiary, with respect to any of its material properties or assets, except liens for taxes not yet due or payable; or 
 (f) any agreement or commitment by the Company or any subsidiary to do any of the things described in this Section 2.14. 

2.15 Tax Returns, Payments and Elections. The Company has timely filed all tax returns (federal, state and local) required to be
filed by it, which tax returns are true and correct in all material respects. The Company has paid all taxes and other assessments due, if any, except those contested by it in good faith that are listed in the Disclosure Letter. Except as set forth
in the Disclosure Letter, none of the Company’s federal income tax returns and none of its state income or franchise tax or sales or use tax returns has ever been audited by governmental authorities and, as of the date hereof, to the
Company’s knowledge, there is no such audit pending or threatened. Since June 30, 2009, the Company has not incurred any taxes, assessments or governmental charges other than in the ordinary course of business and the Company has made
adequate provisions on its books of account for all taxes, assessments and governmental charges with respect to its business, properties and operations for such period. Except as would not constitute a Material Adverse Effect, the Company has
withheld or collected from each payment made to each of its employees, the amount of all taxes (including, but not limited to, federal income taxes, Federal Insurance Contribution Act taxes and Federal Unemployment Tax Act taxes) required to be
withheld or collected therefrom, and has paid the same to the proper tax receiving officers or authorized depositories. 
 2.16
Permits. The Company and its Operating Subsidiaries have all franchises, permits, licenses and any similar authority necessary for the conduct of their respective businesses as now being conducted by them, the lack of which would result in a
Material Adverse Effect. Neither the Company nor any Operating Subsidiary is in default in any material respect under any of such franchises, permits, licenses or other similar authority. To the Company’s knowledge, neither the Company nor any
Operating Subsidiary has received notification of proceedings relating to revocation or modification of any such franchises, permits, licenses or other similar authority. 
 2.17 Environmental and Safety Laws. To the Company’s knowledge, the Company and its subsidiaries are in compliance in all material respects with all applicable statutes, laws and regulations
relating to the environment or occupational health and safety and, to the Company’s knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. Neither the Company nor any
subsidiary has received any written communication from a governmental authority with respect to any material violation of such statutes, laws or regulations. 
  

 9 

 2.18 Disclosure. Neither this Agreement (including all the exhibits and schedules
hereto) nor any certificates made or delivered in connection herewith contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein not misleading in light of the circumstances
under which they were made. 
 2.19 Title to Property and Assets. The property and assets that the Company or any
subsidiary owns are owned by the Company or that subsidiary free and clear of all mortgages, liens, loans and encumbrances, except (i) for statutory liens for the payment of current taxes that are not yet delinquent, (ii) for liens,
encumbrances and security interests that arise in the ordinary course of business and that do not secure indebtedness for borrowed money (which, for clarity, the parties agree does not include accounts payables or other trade payables, capital
leases or accrued expenses) or guarantees thereof, (iii) defects in title, none of which, individually or in the aggregate, materially impair the Company’s or the subsidiary’s ownership or use of such property or assets, and
(iv) liens created in connection with the Debt Financings. With respect to the property and assets the Company or any subsidiary leases, the Company or the subsidiary, as applicable, is in compliance with such leases except where the failure to
be in compliance would not constitute a Material Adverse Effect and, to its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances, subject to clauses (i), (ii) and (iii). 
 2.20 Employee Benefit Plans. The Company does not have or contribute to any “employee benefit plan” as such term is defined
in the Employee Retirement Income Security Act of 1974 (“ERISA”) that is subject to Title IV of ERISA or the funding requirements of Section 412 of the Internal Revenue Code of 1986, as amended. 
 2.21 Labor Agreements and Actions. Neither the Company nor any subsidiary is bound by or subject to any contract, commitment or
arrangement with any labor union. Except as disclosed in the SEC Reports, neither the Company nor any subsidiary is a party to or bound by any currently effective material employment contract, deferred compensation agreement, bonus plan, incentive
plan, profit sharing plan, retirement agreement or other employee compensation agreement. To the Company’s knowledge, the Company and each subsidiary has complied in all material respects with all applicable state and federal equal employment
opportunity and other laws related to employment. 
 2.22 Insurance. The Company and its subsidiaries maintain insurance
coverage of a type and amount customary for entities of similar size engaged in similar lines of business. All of the insurance policies covering the Company and its subsidiaries are in full force and effect. There are no claims in excess of
$100,000 in the aggregate pending against the Company under any insurance policies currently in effect, or by the Company against any of its insurance carriers and covering the property, business or employees of the Company, and all premiums due and
payable with respect to the policies maintained by the Company have been paid. 
 2.23 Fees. Except as set forth in the
Disclosure Letter, the Company has no contract, arrangement or understanding with any broker, finder or similar agent with respect to the transactions contemplated by this Agreement. 
  

 10 

 3. Representations and Warranties of the Investors. Each Investor severally and not
jointly hereby represents, warrants and covenants that: 
 3.1 Authorization. Such Investor has full power and authority
to enter into this Agreement and the Warrants to which it is a party, and each such agreement executed and delivered by such Investor constitutes its valid and legally binding obligation, enforceable in accordance with its terms, except (a) as
limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies, and (c) to the extent the indemnification provisions contained in the Second Amended and Restated Investor Rights Agreement may be limited by applicable federal or state securities
laws. 
 3.2 Purchase Entirely for Own Account. This Agreement is made with such Investor in reliance upon such
Investor’s representation to the Company, which by such Investor’s execution of this Agreement such Investor hereby confirms, that the Series B Preferred Stock and Warrants to be received by such Investor and the Conversion Shares and
Warrant Shares issuable upon conversion or exercise thereof (collectively, the “Securities”) will be acquired for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that such Investor has no present intention of selling, granting any participation in or otherwise distributing the same. By executing this Agreement, such Investor further represents that such Investor does not
have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities. 
 3.3 Disclosure of Information. Such Investor believes it has received all the information it considers necessary or appropriate for
deciding whether to purchase the Series B Preferred Stock. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and
the business, properties, prospects and financial condition of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Investors to rely
thereon. 
 3.4 Investment Experience. Such Investor is an investor in public companies with relatively low market
capitalizations and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the
investment in the Securities. If other than an individual, such Investor also represents it has not been organized for the purpose of acquiring the Securities. 
 3.5 Accredited Investor. Such Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in effect. 
 3.6 Restricted Securities. Such Investor understands that the Securities it is purchasing are characterized as “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such Securities may be resold without
registration under the Act only in certain limited circumstances. In the absence of an effective registration statement covering the Securities or an available exemption from registration under the Act, the Securities must be held indefinitely. In
this connection, such Investor represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act, including without limitation the Rule 144 condition that current
information about the Company be available to the public. 
  

 11 

 3.7 Further Limitations on Disposition. Without in any way limiting the
representations set forth above, such Investor further agrees not to make any disposition of all or any portion of the Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section 3
and the Investor Rights Agreement, provided and to the extent that this Section 3 and the Investor Rights Agreement are then applicable, and: 
 (a) There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (b) (i) Such Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and (ii) if requested by the Company, such Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company that such disposition
will not require registration of such Securities under the Act. 
 Notwithstanding the provisions of subsections (a) and
(b) above, no such registration statement or opinion of counsel shall be necessary for a transfer by an Investor to any affiliated venture capital fund or investment fund, or by an Investor that is a partnership to a partner of such partnership
or a retired partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner or the transfer by gift, will or intestate succession of any partner to his or her spouse or to the siblings, lineal
descendants or ancestors of such partner or his or her spouse, if the transferee agrees in writing to be subject to the terms hereof to the same extent as if he or she were an original Investor hereunder. 
 3.8 Legends. It is understood that the certificates evidencing the Securities may bear one or all of the following legends:

 (a) “THESE SECURITIES HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS, COVERING ANY SUCH TRANSACTION INVOLVING
SAID SECURITIES, (B) THE COMPANY RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION, OR (C) THE COMPANY OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS EXEMPT FROM
REGISTRATION.” 
 (b) Any legend required by applicable laws. 
 3.9 Tax Advisors. Such Investor has reviewed with such Investor’s own tax advisors the federal, state and local tax consequences
of this investment, where applicable, and the transactions contemplated by this Agreement. Each such Investor is relying solely on such advisors and not on any statements or representations of the Company or any of its agents and understands that
each such Investor (and not the Company) shall be responsible for such Investor’s own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 
  

 12 

 3.10 Legal Advisors. Such Investor acknowledges that such Investor has had the
opportunity to review this Agreement, the exhibits and the schedules attached hereto and the transactions contemplated by this Agreement and the Disclosure Letter with such Investor’s own legal counsel. Each such Investor is relying solely on
such Investor’s legal counsel and, except with respect to the opinions to be delivered to the Investors pursuant to Sections 5.4 and 8.4 hereof, not on any statements or representations of the Company or any of the Company’s agents,
including Stradling Yocca Carlson & Rauth PC, for legal advice with respect to this investment or the transactions contemplated by this Agreement. 
 4. Conditions of Investors’ and Company’s Obligations at the Closing. The obligations of each Investor and the Company under Section 1.1(c) of this Agreement are subject to the
satisfaction or, where permitted by law, waiver on or before the Closing of each of the following conditions: 
 4.1 No
Prohibition. No law, statute, rule, regulation, executive order, decree, ruling, injunction or other order (whether temporary, preliminary or permanent) shall have been enacted, entered, promulgated or enforced by any United States or state
court or any governmental entity which prohibits, restrains or enjoins the consummation of the transactions contemplated hereunder. 
 4.2 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the
Series B Preferred Stock and the Warrants in the Closing pursuant to this Agreement shall have been duly obtained and shall be effective as of the Closing, other than such authorizations, approvals or permits or other filings which may be timely
made after the Closing or which, if not obtained, would not materially adversely affect the Company upon consummation of the Closing. 
 4.3 Certificate of Designations. The Certificate of Designations shall have been filed with the Secretary of State of the State of Delaware. 
 4.4 Fairness Opinion. The Company shall have received a fairness opinion in form and substance satisfactory to the Investors, stating, among other things, that the issuance of the Series B
Preferred Stock and the Warrants and the consummation of the Rights Offering is fair from a financial perspective to the stockholders of the Company. 
 5. Additional Conditions of Investors’ Obligations at the Closing. The obligations of each Investor under Section 1.1(c) of this Agreement are also subject to the satisfaction or, where
permitted by law, waiver on or before the Closing of each of the following conditions: 
 5.1 Representations and
Warranties. The representations and warranties of the Company set forth in this Agreement shall be true and correct in all respects (without giving effect to any “materiality,” “Material Adverse Effect” or similar qualifiers
contained in any such representations and warranties, other than any qualifiers contained in any representation or warranty requiring disclosure in the Disclosure Letter of a list of items qualified as to materiality) as of the Closing as though
made on and as of such date (unless any such representation or warranty is made

  

 13 

 
only as of a specific date, in which event such representation and warranty shall be so true and correct as of such specified date), except where the failure of any such representations and
warranties to be so true and correct, in the aggregate, has not had, and would not reasonably be expected to have, a Material Adverse Effect. 
 5.2 Performance. The Company shall have performed and complied in all material respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed
or complied with by it on or before the Closing. 
 5.3 Compliance Certificate. The President of the Company shall
deliver to each Investor at the Closing a certificate in the form attached hereto as Exhibit B stating that the conditions specified in Sections 5.1 and 5.2 have been fulfilled. 
 5.4 Opinion of Company Counsel. Each Investor shall have received from Stradling Yocca Carlson & Rauth PC, counsel for the
Company, an opinion, dated as of the Closing, substantially in the form attached hereto as Exhibit C. 
 5.5
Secretary’s Certificate. Investors shall have received from the Company’s Secretary a certificate in form and substance reasonably satisfactory to the Investors having attached thereto (a) the Company’s Certificate of
Incorporation as in effect at the time of the Closing, (b) the Company’s Bylaws as in effect at the time of the Closing, and (c) resolutions approved by the Company’s board of directors authorizing the transactions contemplated
hereby. 
 5.6 Material Adverse Effect. Since the date of this Agreement, no event shall have occurred which shall have
had a Material Adverse Effect. 
 5.7 Settlement of Investigations. The Company shall have entered into a settlement on
terms satisfactory to the Investors in their sole discretion, with all state and federal regulatory authorities of any currently on-going investigations of the Company and its subsidiaries, and such settlement shall be in full force and effect.

 5.8 Amendments to Debt Financings. The Company shall have entered into an amendment to each of the First Lien Credit
Agreement and the Second Lien Credit Agreement, in each case, in form and substance satisfactory to the Investors in their sole discretion, and all conditions precedent contemplated by such amendments shall have been satisfied, unless the failure to
satisfy any such condition precedent is due to any act or failure to act by the Investors. 
 6. Additional Conditions of the
Company’s Obligations at the Closing. The obligations of the Company under Sections 1.1(c) of this Agreement are also subject to the satisfaction or, where permitted by law, waiver on or before the Closing of each of the following
conditions: 
 6.1 Representations and Warranties. The representations and warranties of the Investors set forth in this
Agreement shall be true and correct in all respects (without giving effect to any “materiality,” “Material Adverse Effect” or similar qualifiers contained in any such representations and warranties as of the Closing as though
made on and as of such date (unless any such representation or warranty is made only as of a specific date, in which event such representation and warranty shall be so true and correct as of such specified date), except where the failure of any such
representations and warranties to be so true and correct, in the aggregate, has not had, and would not reasonably be expected to have, a Material Adverse Effect. 
  

 14 

 6.2 Performance. The Investors shall have performed and complied in all material
respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 
 6.3 Payment of Purchase Price at Closing. The Investors shall have delivered to the Company the aggregate purchase price owed by such Investors for the Series B Preferred Stock being sold hereunder
at the Closing. 
 7. Conditions of Investors’ and Company’s Obligations at the Subsequent Closing. With
respect to the Subsequent Closing, the obligations of each Investor and the Company under Section 1.1(d) of this Agreement are subject to the satisfaction or, where permitted by law, waiver on or before the Subsequent Closing of each of the
following conditions: 
 7.1 Closing. The Closing shall have occurred not more than sixty (60) calendar days prior
to the Subsequent Closing. 
 7.2 No Prohibition. No law, statute, rule, regulation, executive order, decree, ruling,
injunction or other order (whether temporary, preliminary or permanent) shall have been enacted, entered, promulgated or enforced by any United States or state court or any governmental entity which prohibits, restrains or enjoins the consummation
of the transactions contemplated hereunder. 
 7.3 Qualifications. All authorizations, approvals or permits, if any, of
any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Series B Preferred Stock and the Warrants in the Subsequent Closing pursuant to this
Agreement or shall have been duly obtained and shall be effective as of the Subsequent Closing, other than such authorizations, approvals or permits or other filings which may be timely made after the Subsequent Closing or which, if not obtained,
would not materially adversely affect the Company or the Investors upon consummation of the Subsequent Closing. 
 8.
Additional Conditions of Investors’ Obligations at the Subsequent Closing. The obligations of each Investor under Section 1.1(d) of this Agreement are also subject to the satisfaction or, where permitted by law, waiver on or before
the Subsequent Closing of each of the following conditions: 
 8.1 Representations and Warranties. The representations
and warranties of the Company set forth in this Agreement shall be true and correct in all respects (without giving effect to any “materiality,” “Material Adverse Effect” or similar qualifiers contained in any such
representations and warranties, other than any qualifiers contained in any representation or warranty requiring disclosure in the Disclosure Letter of a list of items qualified as to materiality) as of the Subsequent Closing as though made on and as
of such date (unless any such representation or warranty is made only as of a specific date, in which event such representation and warranty shall be so true and correct as of such specified date), except where the failure of any such
representations and warranties to be so true and correct, in the aggregate, has not had, and would not reasonably be expected to have, a Material Adverse Effect. 
  

 15 

 8.2 Performance. The Company shall have performed and complied in all material
respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Subsequent Closing. 
 8.3 Compliance Certificate. The President of the Company shall deliver to each Investor at the Subsequent Closing a certificate in
the form attached hereto as Exhibit B stating that the conditions specified in Sections 8.1 and 8.2 have been fulfilled. 
 8.4 Opinion of Company Counsel. Each Investor shall have received from Stradling Yocca Carlson & Rauth PC, counsel for the Company, an opinion, dated as of the Subsequent Closing, substantially in the form attached hereto as
Exhibit C. 
 8.5 Secretary’s Certificate. Investors shall have received from the Company’s Secretary a
certificate in form and substance reasonably satisfactory to the Investors having attached thereto (a) the Company’s Certificate of Incorporation as in effect at the time of the Subsequent Closing, (b) the Company’s Bylaws as in
effect at the time of the Subsequent Closing, and (c) resolutions approved by the Company’s board of directors authorizing the transactions contemplated hereby. 
 8.6 Material Adverse Effect. Since the date of this Agreement, no event shall have occurred which shall have had a Material Adverse Effect. 
 8.7 Settlement of Investigations. The Company shall have entered into a settlement with all state and federal regulatory authorities
of any currently on-going investigations of the Company and its subsidiaries on terms satisfactory to the Investors in their sole discretion, and such settlement shall be in full force and effect. 
 8.8 Amendments to Debt Financings. The Company shall have entered into an amendment to each of the First Lien Credit Agreement and
the Second Lien Credit Agreement, in each case, in form and substance satisfactory to the Investors in their sole discretion, and all conditions precedent contemplated by such amendments shall have been satisfied, unless the failure to satisfy any
such condition precedent is due to any act or failure to act by the Investors. 
 9. Additional Conditions of the
Company’s Obligations. The obligations of the Company to the Investors under this Agreement in connection with the Subsequent Closing are subject to the satisfaction or, where permitted by law, waiver on or before the Subsequent Closing of
each of the following conditions by that Investor: 
 9.1 Representations and Warranties. The representations and
warranties of the Investors set forth in this Agreement shall be true and correct in all respects (without giving effect to any “materiality,” “Material Adverse Effect” or similar qualifiers contained in any such representations
and warranties as of the Subsequent Closing as though made on and as of such date (unless any such representation or warranty is made only as of a specific date, in which event such representation and warranty shall be so true and correct as of such
specified date), except where the failure of any such representations and warranties to be so true and correct, in the aggregate, has not had, and would not reasonably be expected to have, a Material Adverse Effect. 
  

 16 

 9.2 Performance. The Investors shall have performed and complied in all materials
respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by them before the Subsequent Closing. 
 9.3 Payment of Purchase Price at Subsequent Closing. The Investors shall have delivered to the Company the aggregate purchase price
owed by such Investors for the Series B Preferred Stock being sold hereunder at the Subsequent Closing. 
 10. Covenants.

 10.1 Consent, Information Statement and Certificate of Amendment. 
 (a) Promptly following the Closing, the Company shall (i) obtain the consent of the holders of a majority of the then-outstanding
Series A Preferred Stock to the Certificate of Amendment, which consent shall be in the form attached hereto as Exhibit D-1 (the “Series A Consent”), (ii) obtain the consent of the holders of a majority of the
then-outstanding Series B Preferred Stock to the Certificate of Amendment, which consent shall in the form attached hereto as Exhibit D-2 (the “Series B Consent”) and (iii) obtain the consent of the holders of a majority
of the then-outstanding Common Stock (on an as-converted-to-Common-Stock basis) to the Certificate of Amendment, which consent shall be in the form attached hereto as Exhibit D-3 (together with the Series A Consent and the Series B Consent,
the “Consents”). 
 (b) Promptly after obtaining the Consents, the Company shall prepare and file with the SEC
an information statement in conformance with the rules and regulations under the Exchange Act (the “Information Statement”). The Company shall use reasonable commercial efforts to resolve all SEC comments with respect to the
Information Statement as promptly as practicable after receipt thereof and to cause the Information Statement in definitive form to be cleared by the SEC and mailed to the Company’s stockholders as promptly as reasonably practicable following
filing with the SEC. 
 (c) The Board of Directors of the Company has approved and, upon the execution and delivery of the
Consents, the stockholders constituting the requisite vote will have approved, a Certificate of Amendment to the Restated Certificate of Incorporation of the Company in the form attached hereto as Exhibit A-2 (the “Certificate of
Amendment”), which Certificate of Amendment shall be filed with the Secretary of State of the State of Delaware within three (3) business days after completion of the Information Statement Process. For purposes of this Agreement,
“Information Statement Process” means the filing of an Information Statement pursuant to Section 14C of the Securities Exchange Act of 1934, as amended, relating to the approval by the Company’s stockholders of the
Certificate of Amendment, the mailing of such Information Statement to the stockholders of the Company and the expiration of all related waiting periods pursuant to federal proxy laws and the rules and regulations of the Securities and Exchange
Commission. The Investors hereby acknowledge and agree that they cannot convert the Series B Preferred Stock into Common Stock until the authorized share amount of Common Stock has been increased upon the filing of the Certificate of Amendment.

  

 17 

 10.2 Alternate Financing Proposals. 
 (a) The Company shall promptly notify the Investors within 48 hours of the receipt of any Alternate Financing Proposal after the date
hereof, which notice shall include the material terms of such Alternate Financing Proposal. If (A) the Company’s Board of Directors determines in good faith, after consultation with its financial advisors and outside legal counsel, in
response to an Alternate Financing Proposal, that such proposal is a Superior Proposal, (B) the Company notifies the Investors in writing of the terms of the Superior Proposal and the determinations described in clause (A) above and of its
intent to terminate this Agreement, (C) the Company’s Board of Directors takes into account any revised proposal made by the Investors to the Company (a “Revised Investor Proposal”) within three (3) business days
after the Investors’ receipt of such notice and again determines in good faith after consultation with its outside legal counsel and independent financial advisors that such Alternate Financing Proposal (as the same may have been modified or
amended) remains a Superior Proposal, and (D) the Company’s Board of Directors, if a Revised Investor Proposal has been made, and such Alternate Financing Proposal had been modified or amended prior to the Board’s re-determination
referred to in clause (C) above, (x) first, notifies the Investors of the revised terms of such Alternate Financing Proposal; (y) second, establishes a deadline, and notifies the Investors and the person making such Alternate
Financing Proposal thereof, to occur not less than three (3) nor more than seven (7) business days after giving such notice, for the submission of final proposals from both the Investors and such person; and (z) within seven
(7) business days after such deadline, again determines in good faith after consultation with its outside legal counsel and independent financial advisors that such Alternate Financing Proposal remains a Superior Proposal and notifies the
Investors of such determination, the Company or its Board of Directors may terminate this Agreement in order to enter into a definitive agreement with respect to such Superior Proposal. 
 (b) For purposes of this Agreement, the following terms shall have the meanings assigned below: 
 (i) “Alternate Financing Proposal” means any inquiry, proposal or offer from any Person or group of Persons (other than
the Investors) relating to (i) any proposal or offer concerning an alternate financing for the Company’s general and working capital needs or (ii) any proposal or offer concerning an acquisition of all or substantially all of the
issued and outstanding capital stock of the Company or an acquisition of all or substantially all the assets of the Company. 
 (ii) “Superior Proposal” means any Alternate Financing Proposal (x) on terms more favorable to the Company than the transactions contemplated by this Agreement, taking into account all of the terms and conditions of
such proposal and this Agreement (including any proposal to amend the terms of the transactions contemplated by this Agreement, the First Lien Credit Agreement or the Second Lien Credit Agreement), and (y) that the Board of Directors of the
Company determines in good faith is reasonably capable of being completed, taking into account the identity of the person or persons making the proposal and all financial, regulatory, legal and other aspects of such proposal. 
 10.3 Further Assurances. Subject to the terms and conditions of this Agreement, each party will use its reasonable commercial efforts
to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper or advisable under applicable laws and regulations to consummate the transactions contemplated by this Agreement. 
 10.4 Public Statements. Each of the Company and the Investors agrees that no public release or announcement concerning the
transactions contemplated hereby shall be issued without the prior written consent of the Company or the Investors, except as such release or

  

 18 

 
announcement may be required by law or the rules or regulations of any applicable securities exchange or regulatory or governmental body to which the relevant party is subject, wherever situated,
in which case the party required to make the release or announcement shall use its reasonable commercial efforts to provide the Company or the Investors, as the case may be, reasonable time to comment on such release or announcement in advance of
such issuance, it being understood that the final form and content of any such release or announcement, to the extent so required, shall be at the final discretion of the disclosing party. 
 10.5 Reservation of Shares. From and after the filing of the Certificate of Amendment, the Company shall take all action necessary to
at all times have authorized, and reserved for the purpose of issuance, no less than 100% of the number of shares of Common Stock needed to provide for the issuance of the Conversion Shares upon full conversion of all outstanding shares of Series B
Preferred Stock and the Warrant Shares upon the full exercise of all outstanding Warrants. 
 10.6 Rights Offering.
Within six months of the Closing, the Company shall offer for purchase (the “Rights Offering”) to each holder of Common Stock and Series A Preferred Stock of the Company shares of Series B Preferred Stock at a per share price equal
to the Per Share Price (the “Rights Offering Price”). The number of shares of Series B Preferred Stock offered to each such holder shall be equal to the product obtained by multiplying (A) the aggregate number of shares of
Common Stock and Series A Preferred Stock owned or held by such holder (on an as-converted-to-Common-Stock basis) by (B) the quotient obtained by dividing (i) the number of shares of Series B Preferred Stock purchased by the Investors
hereunder by (ii) the aggregate number of shares of Series A Preferred Stock (on an as-converted-to-Common-Stock basis) and Common Stock owned or held by the Investors immediately prior to the Closing. 
 11. Termination. 
 11.1 Termination. This Agreement may be terminated: 
 (a) by mutual written consent of the Investors and the
Company; 
 (b) by the Investors or the Company if any court of competent jurisdiction or other governmental entity shall have
issued a final order, decree or ruling or taken any other final action restraining, enjoining or otherwise prohibiting the transactions contemplated hereunder and such order, decree, ruling or other action is or shall have become final and
nonappealable; 
 (c) by either the Investors or the Company if: 
 (i) the Closing shall not have occurred on or before December 14, 2009; provided, however, that the right to terminate this Agreement
pursuant to this Section 11.1(c)(i) shall not be available to the party seeking to terminate unless the party seeking to terminate pursuant to this Section 11.1(c)(i) shall not have been the cause of the failure of the Closing to occur on
or before such date and such action or failure to perform constitutes a breach of this Agreement; or 
  

 19 

 (ii) the Subsequent Closing shall not have occurred on or before February 12, 2010;
provided, however, that the right to terminate this Agreement pursuant to this Section 11.1(c)(ii) shall not be available to the party seeking to terminate unless the party seeking to terminate pursuant to this Section 11.1(c)(ii) shall
not have been the cause of the failure of the Subsequent Closing to occur on or before such date and such action or failure to perform constitutes a breach of this Agreement; 
 (d) by the Company: 
 (i) if there shall have been a breach of any representation, warranty, covenant or agreement on the part of the Investors such that the conditions set forth in Sections 4, 6, 7 and 9 would not be satisfied and, in either such case, such
breach is not cured or curable by (A) in respect of the Closing and the conditions thereto, the date on which all other conditions to consummate the transactions contemplated by this Agreement have been satisfied, and (B) in respect of the
Subsequent Closing and the conditions thereto, the date on which all other conditions to consummate the transactions contemplated by this Agreement have been satisfied; or 
 (ii) in accordance with, and subject to the terms and conditions of, Section 10.3(a); or 
 (e) by Investors who have agreed to purchase a majority of the Shares of Series B Preferred Stock to be sold in connection with the Closing
if there shall have been a breach of any representation, warranty, covenant or agreement on the part of the Company contained in this Agreement such that the conditions set forth in Sections 4, 5, 7 and 8 would not be satisfied and, in either such
case, such breach is not cured or curable by (A) in respect of the Closing and the conditions thereto, the date on which all other conditions to consummate the transactions contemplated by this Agreement have been satisfied, and (B) in
respect of the Subsequent Closing and the conditions thereto, the date on which all other conditions to consummate the transactions contemplated by this Agreement have been satisfied. 
 11.2 Effect of Termination. In the event of the termination of this Agreement pursuant to Section 11.1, this Agreement shall
forthwith become void and there shall be no liability or obligation on the part of any party hereto, except as provided in Section 10.6, this Section 11.2 and Section 12, which shall survive such termination; provided, however, that
nothing herein shall relieve any party from liability for any breach of this Agreement. 
 12. Miscellaneous. 

12.1 Survival. The warranties, representations and covenants of the Company and Investors contained in or made pursuant to this
Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company. 
 12.2 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any securities). Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or
their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  

 20 

 12.3 Governing Law. This Agreement shall be governed by and construed under the laws
of the State of California without regard to principles of conflicts of law. 
 12.4 Titles and Subtitles. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 12.5 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent
by confirmed telex or facsimile or by electronic mail if sent during normal business hours of the recipient, if not, then on the next business day; (c) five days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the address as set forth on the signature page
hereof or at such other address as such party may designate by ten days’ advance written notice to the other parties hereto. 
 12.6 Finder’s Fee. Each party represents that, except as set forth in the Disclosure Letter or in this Section 12.6, it neither is nor will be obligated for any finder’s fee or commission in connection with this
transaction. Each Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted
liability) for which such Investor or any of its officers, partners, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the nature of
a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
 12.7 Expenses; Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this
Agreement, the Certificate of Designations or the Warrants, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

12.8 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), (i) prior to the Closing, only with the written consent of the Company and Investors acquiring in the aggregate more than half the shares of Series
B Preferred Stock to be sold pursuant hereto, (ii) after the Closing but prior to the Subsequent Closing, only with the written consent of the Company, Investors acquiring in the aggregate more than half of the shares of Series B Preferred
Stock to be issued at the Subsequent Closing and the holders of a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock sold at the Closing pursuant to this Agreement and (iii) after the Subsequent
Closing, only with the written consent of the Company and the holders of a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock sold pursuant to this Agreement. Any amendment or waiver effected in
accordance with this Section 12.8 shall be binding upon each holder of any securities purchased under this Agreement (including securities into which such securities are convertible) at the time outstanding, each future holder of all such
Series B Preferred Stock and the Company. The failure of any party to assert any rights or remedies shall not constitute a waiver of such rights or remedies. 
  

 21 

 12.9 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

12.10 Aggregation of Stock. All shares of the Series B Preferred Stock held or acquired by affiliated entities or persons shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 12.11 Entire
Agreement. This Agreement and the documents, schedules and exhibits referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations or
covenants except as specifically set forth herein or therein. 
 12.12 Counterparts. This Agreement may be executed in
two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [SIGNATURE PAGES FOLLOW] 
  

 22 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMPANY:
	
	PURPLE COMMUNICATIONS, INC.
		
	By:	 	 /s/ Daniel R. Luis

	Name:	 	Daniel R. Luis
	Title:	 	Chief Executive Officer
	Address:	 	

  

			
		 	Attn.: Chief Executive Officer
		
	With a copy to:	 	
		
		 	Stradling Yocca Carlson & Rauth PC
		
		 	660 Newport Center Drive, Suite 1600
		 	Newport Beach, CA 92660
		
		 	Attn.: Michael E. Flynn, Esq.
		
		 	Fax No. (949) 725-4100

 [SIGNATURE PAGE TO SERIES B PREFERRED STOCK PURCHASE AGREEMENT] 
  

 23 

			
	INVESTOR:
	
	CCP A, L.P.
		
	By:	 	CLEARLAKE CAPITAL PARTNERS, LLC
		 	Its General Partner
		
	By:	 	CCG Operations, LLC
		 	Its Managing Member
		
	By:	 	 /s/ Behdad Eghbali

	Name:	 	Behdad Eghbali
	Title:	 	Authorized Signatory
	Address:	 	650 Madison Avenue, 26th Floor
		
		 	New York, NY 10022
		
		 	Fax No. (212) 610-9121
	
	With a copy to:
		
		 	Milbank, Tweed, Hadley & McCloy LLP
		 	601 S. Figueroa St., 30th Floor
		 	Los Angeles, CA 90017
		
		 	Attn.: Melainie K. Mansfield, Esq.
		
		 	Fax No. (213) 892-4711

 [SIGNATURE PAGE TO SERIES B PREFERRED STOCK PURCHASE AGREEMENT] 
  

 24 

 SCHEDULE A 
 Schedule of Investors 
 Part I 
  

						
	 Investor
	  	Purchase Price	  	Shares of Series B
Preferred
Stock
	 CCP A, L.P.
	  	$	1,999,999.50	  	1,333,333
	 Total
	  	$	1,999,999.50	  	

 Part II 
  

						
	 Investor
	  	Purchase Price	  	Shares of Series B
Preferred
Stock
	 CCP A, L.P.
	  	$	3,000,000.00	  	2,000,000
	 Total
	  	$	3,000,000.00	  	

  

 25 

 Exhibit A-1 
 Form of Certificate of Designations 
 CERTIFICATE OF DESIGNATIONS, PREFERENCES
AND RIGHTS OF 
 SERIES B PREFERRED STOCK 
 of 
 PURPLE COMMUNICATIONS, INC. 
 Pursuant to Sections 103 and 151 of the General Corporation Law 
 of the State of Delaware 
 I, the undersigned, Dan Luis, Chief Executive Officer
of Purple Communications, Inc., a Delaware corporation (hereinafter called the “Corporation”), pursuant to the provisions of Sections 103 and 151 of the General Corporation Law of the State of Delaware, do hereby make this
Certificate of Designations and do hereby state and certify that pursuant to the authority expressly vested in the Board of Directors of the Corporation by the Certificate of Incorporation of the Corporation, as amended (the “Certificate of
Incorporation”), the Board of Directors duly adopted the following resolutions: 
 RESOLVED, that, pursuant to Article
4 of the Certificate of Incorporation (which authorizes an aggregate of 11,671,180 shares of preferred stock, $0.01 par value (“Preferred Stock”)), the Board of Directors hereby fixes the powers, designations, preferences and
relative, participating, optional and other special rights, and the qualifications, limitations and restrictions, of a series of Preferred Stock. 
 RESOLVED, that each share of such series of Preferred Stock shall rank equally in all respects and shall be subject to the following provisions: 
 13. Number and Designation. 3,333,333 shares of the Preferred Stock of the Corporation shall be designated as Series B Preferred Stock (the
“Series B Preferred Stock”). 
 14. Rights, Preferences and Restrictions of Series B Preferred Stock. 
 14.1 Dividend Provisions. 
 (a) Dividend Amount. 
 (i) Cumulative Dividends. Each outstanding
share of Series B Preferred Stock shall accrue cash dividends commencing on the date such share of Series B Preferred Stock is first issued (as to each such share, the “Series B Issue Date”). The holders of shares of Series B
Preferred Stock shall be entitled to receive, when, as and if declared by the Board, out of any assets legally available therefor, cumulative cash dividends (the “Cumulative Dividend”) at the rate of: 
 (x) for each share of Series B Preferred Stock issued prior to the Dividend Reduction Date, (I) 12% of the face amount per annum,
compounded quarterly from and including the Series B Issue Date to but excluding the Dividend Reduction Date and (II) 8% of the face amount per annum, compounded quarterly from and including the Dividend Reduction Date; and 
  

 1 

 (y) for each share of Series B Preferred Stock issued on or after the Dividend Reduction
Date, 8% of the face amount per annum, compounded quarterly from and including the Series B Issue Date. 
 (ii)
Participation as to Dividends. To the extent dividends are paid by the Corporation on shares of Common Stock (in anything other than additional shares of Common Stock for which a corresponding adjustment is made to the Series B Preferred
Stock Conversion Price hereunder), holders of outstanding shares of Series B Preferred Stock shall also be entitled to receive, during each fiscal year, an amount (if greater than zero) equal to (x) dividends payable on shares of Common Stock,
if any, during such fiscal year (as if such shares of Series B Preferred Stock had been converted into Common Stock on the record date for such Common Stock dividend) minus (y) the amount of Cumulative Dividends that have been paid or
have accrued during such fiscal year pursuant to Section B.1.(a)(i) of this Article IV. 
 (b) Priority.
Cumulative Dividends shall be paid prior and in preference to any declaration or payment of any dividend (other than a dividend paid only in additional shares of Common Stock of the Corporation) on the Common Stock of the Corporation, but after and
junior to any declaration or payment of any dividend on the Series A Preferred Stock of the Corporation, except as permitted by this Section 1(b). Any dividends paid on the Series B Preferred Stock shall be paid ratably among the holders
of Series B Preferred Stock outstanding as of the applicable record date. 
 (c) Definitions. Unless the context
otherwise requires, the terms defined in this Section (1)(c) of Article IV.B. shall have, for all purposes of this Amended and Restated Certificate of Incorporation, the meanings herein specified (with terms defined in the
singular having comparable meanings when used in the plural): 
 “Closing Price” shall mean, with
respect to the Corporation’s Common Stock on any date, the closing price on such date as reported on the National Association of Securities Dealers Automated Quotation System (“NASDAQ”) or the principal U.S. securities
exchange on which the Corporation’s Common Stock is then listed, or, if the Corporation’s Common Stock is not quoted on NASDAQ and is not listed on a U.S. securities exchange, as reported on the principal other market on which the
Corporation’s Common Stock is then traded. In the absence of such quotations, the Closing Price shall be deemed to be zero. 
 “Dividend Reduction Date” shall mean the first day after the date that is one (1) year following the date this Certificate of Designations is filed with the Secretary of State of the State of Delaware upon which
the average Closing Price of the Corporation’s Common Stock over the Trading Days within the 90-day period immediately preceding such date is $15.00 or more per share (as adjusted for subsequent stock dividends, splits, combinations or similar
events). 
 “Trading Day” shall mean (x) if the Corporation’s Common Stock is quoted on
NASDAQ, a day on which trades may be made thereon, (y) if the Corporation’s Common Stock is listed or admitted for trading on another U.S. securities exchange, a day on which such other U.S. securities exchange is open for business or
(z) if the Corporation’s Common Stock is not quoted on NASDAQ and is not listed or admitted for trading on another U.S. securities exchange, a weekday on which commercial banks are open for business in the State of New York. 
  

 2 

 14.2 Liquidation. 
 (a) Series B Liquidation Preference. In the event of any liquidation, dissolution or winding up of the Corporation
(“Liquidation”), whether voluntary or involuntary, the holders of Series B Preferred Stock shall be entitled to receive for each outstanding share of Series B Preferred Stock, prior and in preference to any distribution of
any of the assets of the Corporation to the holders of the Common Stock by reason of their ownership thereof, but after and junior to any distribution of any of the assets of the Corporation to the holders of the Series A Preferred Stock by reason
of their ownership thereof, an amount per share equal to $1.50 (as adjusted for subsequent stock dividends, splits, combinations or similar events with respect to the Series B Preferred Stock) (“Series B Issue Price”), plus
an amount equal to all accrued but unpaid Cumulative Dividends and any other accrued but unpaid dividends on such share payable hereunder (the “Series B Liquidation Amount”). If, upon the occurrence of such event, the assets
and funds thus distributed among the holders of the Series B Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amounts aforesaid, then, all of the assets available for distribution to holders of the
Series B Preferred Stock shall be distributed among and paid to such holders ratably in proportion to the number of shares of Series B Preferred Stock held by such holders. Upon payment of the full preferential amounts set forth above in respect of
a share of Series B Preferred Stock, such share of Series B Preferred Stock shall be immediately surrendered and canceled without any further action on the part of the Corporation or the holder thereof. 
 (b) Remaining Assets. Upon the completion of the distribution required by subparagraph (a) of this Section 2,
in the event of a Liquidation, the remaining assets of the Corporation available for distribution to stockholders shall be distributed among the holders of Common Stock pro rata based on the number of shares of Common Stock held by each. 

(c) Deemed Liquidation. 
 (i) For purposes of this Section 2, a Liquidation shall be deemed to be occasioned by, or to include, the following (each of the following, as so qualified, a “Liquidation
Event”), unless the holders of a majority of the then outstanding shares of Series B Preferred Stock and the Corporation consent in writing that such event or transaction or series of transactions shall not be deemed a Liquidation:

 (A) the acquisition of the Corporation by another entity by means of any transaction or series of related transactions
(including, without limitation, any reorganization, merger or consolidation, but excluding (x) any merger effected exclusively for the purpose of changing the domicile of the Corporation and (y) any transaction or series of transactions in
which the beneficial owners (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the stock of the Corporation having the right to vote for the election of members of
the Corporation’s board of directors immediately prior to the consummation of such transaction or transactions are the beneficial owners (as defined in Rule 13d-3 under the Exchange Act) of more than 50% of the stock of the successor
entity having the right to vote for the election of members of such successor entity’s board of directors immediately after the consummation of such transaction or transactions); 
  

 3 

 (B) a sale of all or substantially all of the assets of the Corporation and its
subsidiaries; or 
 (C) a Change of Control of the Corporation. 
 As used herein, “Change of Control of the Corporation” means (1) any “person” or “group” (within the meaning of Sections 13(d) and 14(d) of the
Exchange Act) becoming the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) after the first date on which any shares of Series B Preferred Stock were issued (the “Initial Series B Issue Date”), directly
or indirectly, of more than 50% of the then outstanding voting power of the capital stock of the Corporation or (2) any “person” or two or more “persons” (within the meaning of Sections 13(d) and 14(d) of the Exchange
Act) acting in concert shall have acquired by contract or otherwise, or shall have entered into a contract or arrangement that, upon consummation thereof, will result in its or their acquisition of the power to exercise, directly or indirectly, a
controlling influence over the management or policies of the Corporation or control of more than 50% of the then outstanding voting power of the capital stock of the Corporation. 
 (ii) In any Liquidation Event, if the consideration received by the Corporation is other than cash or securities, its value will be deemed
its fair market value, as determined in good faith by the Board. The fair market value of any securities shall be valued as follows: 
 (A) Securities not subject to investment letter or other similar restrictions on free marketability covered by (B) below: 
 (1) If traded on a national securities exchange, the value shall be deemed to be the average of the Closing Prices of the securities on such exchange or market over the thirty (30)-Trading Day period
ending three (3) days prior to the closing; 
 (2) If actively traded over-the-counter, the value shall be deemed to be
the average of the closing bid or sale prices (whichever is applicable) over the thirty (30)-Trading Day period ending three (3) days prior to the closing; and 
 (3) If there is no active public market, the value shall be the fair market value thereof, as mutually determined in good faith by the Board and the holders of at least a majority of the shares of the
Series B Preferred Stock then outstanding or, if such parties cannot agree on such value, within five (5) business days from the date that either party determines that the fair market value cannot be agreed upon, a national (or otherwise
well-recognized) investment banking firm with expertise in valuation. 
 (B) The method of valuation of securities subject to
investment letter or other restrictions on free marketability (other than restrictions arising solely by virtue of a stockholder’s status as an affiliate or former affiliate) shall be to make an appropriate discount from the market value
determined as above in (A)(1), (2) or (3) to reflect the approximate fair market value thereof, in each case, as determined by a national (or otherwise well-recognized) investment banking firm with expertise in valuation. 
  

 4 

 (iii) The Corporation shall give each holder of record of Series B Preferred Stock written
notice of such impending transaction not later than the earlier of (A) fourteen (14) days prior to the stockholders’ meeting called to approve such transaction, or (B) fourteen (14) days prior to the closing of such
transaction, and shall also promptly notify such holders in writing of the final approval of such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction and the provisions of this
Section 2, and the Corporation shall thereafter give holders of Series B Preferred Stock prompt notice of any material modifications of such terms and conditions of such impending transaction. The transaction shall in no event take place
sooner than fourteen (14) days after the Corporation has given the first notice provided for herein or sooner than ten (10) days after the Corporation has given notice of any material changes provided for herein; provided, however, that
such periods may be shortened or waived with the written consent of the holders of a majority of the shares of Series B Preferred Stock then outstanding. 
 14.3 Redemption. 
 (a) If any holder of shares of Series B Preferred Stock
shall elect at any time after January 10, 2016 that the Corporation shall redeem (to the extent it may lawfully do so) the number of shares of Series B Preferred Stock held by such holder that is specified in a request for redemption delivered
to the Corporation by the holder (accompanied by the certificates representing the shares of Series B Preferred Stock to be so redeemed), the Corporation shall promptly honor such request for redemption (to the extent of lawfully available funds
therefor), by paying in cash on the Redemption Date an amount equal to the Series B Redemption Price. 
 (b) The Corporation may
at any time (to the extent it may lawfully do so and to the extent it is permitted to do so by the terms of its outstanding debt and equity securities), but no earlier than January 10, 2016, at the option of the Board of Directors, redeem (to
the extent there are lawfully available funds therefor) in whole or in part the Series B Preferred Stock by paying in cash therefor an amount equal to the Series B Redemption Price on the Redemption Date. The terms of any redemption pursuant to this
Section 3(b) shall be specified in the Corporation Redemption Notice (as defined below). Any redemption effected pursuant to this Section 3(b) shall be made on a pro rata basis among the holders of the Series B Preferred
Stock in proportion to the number of shares of Series B Preferred Stock then held by them. 
 (c) As used herein, the term
“Redemption Date” shall refer to (i) in the case of redemption pursuant to Section 3(a) of this Article IV.B., the date that is designated by the Corporation in the Redemption Notice (as defined
below) and which shall not be more than 25 days after the Corporation’s receipt of a request for redemption, and (ii) in the case of a redemption pursuant to Section 3(b) of this Article IV.B., the date designated
by the Corporation in the Corporation Redemption Notice (as defined below) upon which a redemption is to be effected. As used herein, the term “Series B Redemption Price” shall have the same meaning as Series B Liquidation
Amount. 
 (d) Upon receipt of a request for redemption pursuant to Section 3(a) of this Article IV.B.
(the “Exercise Notice”) within ten (10) days of the receipt of the Exercise Notice, the Corporation shall give written notice to each holder of record of the Series B Preferred Stock (as of the close of business on the
business day next preceding the day on which notice is given), at the address last shown on the records of the Corporation for such holder, notifying such holder of the receipt of the Exercise Notice, the Redemption Date, the Series B Redemption
Price, the place at which payment may be obtained and calling upon such holder to surrender to the Corporation, in the manner and at the place designated, his certificate or certificates representing the shares to be 
  

 5 

 redeemed (the “Redemption Notice”). Each holder of the Series B Preferred Stock
shall have the right to participate in the redemption described in the Redemption Notice by delivering to the Corporation, within ten (10) days of his receipt of the Redemption Notice, a written request to participate in such redemption, which
request shall specify the number of shares of Series B Preferred Stock such holder is requesting that the Corporation redeem. In the event that multiple holders request such redemption and the Corporation does not have sufficient funds lawfully
available to accommodate all such requests, such redemption shall be made on a pro rata basis among the holders of the Series B Preferred Stock requesting redemption in proportion to the number of shares of Series B Preferred Stock specified in each
such holder’s request for redemption. 
 (e) In the case of a redemption pursuant to Section 3(b) of this
Article IV.B., the Corporation shall give written notice to each holder of record (as of the close of business on the business day next preceding the day on which notice is given), at the address last shown on the records of the
Corporation for such holder, notifying such holder of the redemption to be effected, specifying the number of shares to be redeemed from such holder, the Redemption Date (which may be the date of the notice if payment of the Redemption Price is made
on such date), the Redemption Price, the place at which payment may be obtained and calling upon such holder to surrender to the Corporation, in the manner and at the place designated, his certificate or certificates representing the shares to be
redeemed (the “Corporation Redemption Notice”). If the funds of the Corporation legally available for redemption of shares of Series B Preferred Stock on a Redemption Date triggered pursuant to Section 3(b) of
this Article IV.B. are insufficient to redeem the total number of shares of Series B Preferred Stock to be redeemed on such date, those funds which are legally available will be used to redeem the maximum possible number of such shares
ratably among the holders of such shares to be redeemed based upon their holdings of Series B Preferred Stock. The shares of Series B Preferred Stock not redeemed shall remain outstanding and entitled to all the rights and preferences provided
herein. At any time thereafter when additional funds of the Corporation are legally available for the redemption of shares of Series B Preferred Stock such funds will immediately be used to redeem the balance of the shares which the Corporation has
become obliged to redeem on any such Redemption Date but which it has not redeemed. 
 (f) On or prior to a Redemption Date,
each holder of shares of Series B Preferred Stock to be redeemed on such date shall surrender to this Corporation the certificate or certificates representing such shares, in the manner and at the place designated in the Redemption Notice or the
Corporation Redemption Notice, as applicable, and thereupon the Series B Redemption Price of such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof and each surrendered
certificate shall be canceled. In the event less than all the shares represented by any such certificate are redeemed, a new certificate shall be issued representing the unredeemed shares. 
 (g) From and after payment of the Series B Redemption Price, all rights of the holders of the shares of Series B Preferred Stock so
redeemed, as holders of such shares of Series B Preferred Stock, shall cease with respect to such redeemed shares, and such shares shall not thereafter be transferred on the books of the Corporation or be deemed to be outstanding for any purpose
whatsoever. 
  

 6 

 14.4 Conversion. The holders of the Series B Preferred Stock shall have the following
conversion rights: 
 (a) Right to Convert. Each share of Series B Preferred Stock shall be convertible, at the option of
the holder thereof, at any time after the date of issuance of such share at the office of the Corporation or any transfer agent for the Series B Preferred Stock, into such number of fully paid and nonassessable shares of Common Stock as is
determined by dividing (1) the Series B Issue Price plus the amount of all accrued and unpaid Cumulative Dividends and any other accrued but unpaid dividends on such Series B Preferred Stock by (2) the Conversion Price at the time in
effect for the Series B Preferred Stock. The “Conversion Price” per share for shares of Series B Preferred Stock shall initially be equal to $0.15 (as adjusted pursuant to Section 4(b) of this Article IV.B.
below). 
 (b) Adjustments to the Conversion Price. The Conversion Price of the Series B Preferred Stock shall be subject
to adjustment from time to time as follows: 
 (i)(A) Subject to Section 4(b)(v) of this
Article IV.B. below, if this Corporation shall issue, after the Initial Series B Issue Date, any Additional Stock (as defined below) without consideration or for a consideration per share less than the Conversion Price for such series in
effect immediately prior to the issuance of such Additional Stock, the Conversion Price for the Series B Preferred Stock in effect immediately prior to each such issuance shall forthwith (except as otherwise provided in this clause (i)) be
adjusted to a price equal to the consideration per share received by this Corporation for such issuance. 
 (B) Except to the
limited extent provided for in subsections (E) of this Section below, no adjustment of such Conversion Price pursuant to this subsection 4(b)(i) shall have the effect of increasing the Conversion Price above the Conversion
Price in effect immediately prior to such adjustment. 
 (C) In the case of the issuance of Common Stock for cash, the
consideration shall be deemed to be the amount of cash paid therefor before deducting any reasonable discounts, commissions or other expenses allowed, paid or incurred by this Corporation for any underwriting or otherwise in connection with the
issuance and sale thereof. 
 (D) In the case of the issuance of the Common Stock for a consideration in whole or in part other
than cash, the consideration other than cash shall be deemed to be the fair value thereof determined in accordance with Section 2(c)(ii) of this Article IV.B. 
 (E) In the case of the issuance (whether before, on or after the Initial Series B Issue Date) of options to purchase or rights to subscribe
for Common Stock, securities by their terms convertible into or exchangeable for Common Stock or options to purchase or rights to subscribe for such convertible or exchangeable securities, such options to purchase or rights to subscribe for Common
Stock shall be deemed to have been issued at the time such options or rights were issued and for a consideration equal to the consideration determined in the manner provided in subsections 4(b)(i)(C) and 4(b)(i)(D) of this Subsection (B), if any,
received by this Corporation upon the issuance of such options or rights plus the minimum exercise price provided in such options or rights (taking into account potential antidilution adjustments) for the Common Stock covered thereby; provided,
however, that, upon the expiration of any such options or rights, the termination of any such rights to convert or exchange or the expiration of any options or rights related to such convertible or exchangeable securities prior to the
conversion, exchange, or exercise thereof, the Conversion Price of the Series B Preferred Stock, to the extent adjusted only as a result of the issuance of such options, rights or securities or options or rights related to such securities, shall
revert to the Conversion Price in effect prior to such issuance of such options, rights or securities or options or rights related to such securities. 
  

 7 

 (ii) “Additional Stock” shall mean any shares of Common Stock
issued (or deemed to have been issued pursuant to subsection 4(b)(i)(E) of this Subsection B) by this Corporation after the Initial Series B Issue Date other than: 
 (A) shares of Common Stock issued pursuant to a transaction described in subsection 4(b)(iii) of this Subsection B;

 (B) shares of Common Stock issuable or issued to employees, consultants or directors of this Corporation pursuant to a stock
option plan or restricted stock plan approved by the Board; 
 (C) shares of Common Stock issued or issuable in a bona fide,
underwritten public offering of shares of Common Stock; 
 (D) shares of Common Stock issued or issuable upon conversion of
Series B Preferred Stock or as dividends or distributions on the Series B Preferred Stock, or upon exercise of options or warrants or conversion of any other convertible securities outstanding as of the Initial Series B Issue Date; 
 (E) shares of Common Stock issued in connection with a bona fide business acquisition of or by this Corporation that is approved by the
Board, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise; 
 (F) shares of Common Stock
issued or issuable upon exercise of warrants or other securities or rights pursuant to equipment lease financings or bank credit arrangements approved by the Board and not undertaken for the primary purpose of raising equity capital; or 

(G) shares of Common Stock issued or issuable upon exercise of warrants or other securities or rights to persons or entities with which
this Corporation has business relationships or corporate partnering arrangements, including without limitation, the acquisition of technology, and provided that such issuances are approved by the Board and not undertaken for the primary purpose of
raising equity capital. 
 (iii) In the event this Corporation should at any time or from time to time after the Initial Series
B Issue Date, fix a record date for the effectuation of a split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional
shares of Common Stock or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock (hereinafter referred to as “Common Stock
Equivalents”) without payment of any consideration by such holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion or exercise thereof),
then, as of such record date (or the date of such dividend, distribution, split or subdivision if no record date is fixed), the Conversion Price of the Series B Preferred Stock shall be appropriately decreased so that the number of shares of Common
Stock issuable on conversion of each share of such series shall be increased in proportion to such increase of the aggregate of shares of Common Stock outstanding and those issuable with respect to such Common Stock Equivalents. 
  

 8 

 (iv) If the number of shares of Common Stock outstanding at any time after the Initial
Series B Issue Date is decreased by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the Conversion Price for the Series B Preferred Stock shall be appropriately increased so that the
number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in outstanding shares. 
 (v) No adjustment in the number of shares into which the Preferred Stock is convertible shall be made, by adjustment of the applicable Conversion Price or otherwise, if, prior to such issuance, this
Corporation receives written notice from the holders of at least two-thirds of the then outstanding shares of Series B Preferred Stock that would otherwise be entitled to such adjustment agreeing that no such adjustment shall be made to the
Conversion Price in connection with such issuance. 
 (c) Mechanics of Conversion. Before any holder of Series B
Preferred Stock shall be entitled to convert the same into shares of Common Stock, such holder shall surrender the certificate or certificates representing such holder’s shares of Series B Preferred Stock, duly endorsed, at the office of the
Corporation or of any transfer agent for the Series B Preferred Stock and shall give written notice by mail, postage prepaid, to the Corporation at its principal corporate office, of the election to convert the same and shall state therein the name
or names in which the certificate or certificates representing shares of Common Stock are to be issued. The Corporation shall, as soon as practicable thereafter, issue and deliver to such holder of Series B Preferred Stock, or to the nominee or
nominees of any such holder, a certificate or certificates representing the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the close of
business on the date of such surrender of the shares of Series B Preferred Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record
holder or holders of such shares of Common Stock as of such date. If the conversion is in connection with a Liquidation Event, the conversion may, at the option of the holder tendering Series B Preferred Stock for conversion, be contingent upon, and
be deemed to have occurred immediately prior to, the closing of such Liquidation Event. 
 (d) No Fractional Shares. No
fractional shares shall be issued upon conversion of the Series B Preferred Stock. In lieu of issuing any fractional shares to which such stockholder is entitled, the Corporation shall pay cash equal to the product of such fraction multiplied by the
fair value of the Common Stock (as determined by the Board) on the date of conversion. Whether or not fractional shares are issuable upon such conversion shall be determined on the basis of the total number of shares of Series B Preferred Stock held
by the holder at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. 
 (e) Reservation of Stock Issuable Upon Conversion. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock solely for the purpose of
effecting the conversion of shares of the Series B Preferred Stock such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Series B Preferred Stock; and if at any time
the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then

  

 9 

 
outstanding shares of the Series B Preferred Stock, in addition to such other remedies as shall be available to the holder of such Series B Preferred Stock, the Corporation will take such
corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. Notwithstanding anything contained herein to the contrary, until such time as the
authorized but unissued shares of Common Stock are sufficient to permit the full conversion of the outstanding Series A Preferred Stock and Series B Preferred Stock, the Series B Preferred Stock shall not be convertible into shares of Common Stock
to the extent that there are not sufficient shares to permit such conversion. 
 (f) Automatic Conversion. 
 (i) After completion of an underwritten public offering of the Corporation’s Common Stock yielding proceeds of at least $50,000,000
before deducting underwriters’ commissions and discounts and offering expenses, on the first day that the average Closing Price of the Corporation’s Common Stock over the Trading Days within the 90-day period immediately preceding such
date is $15.00 or more per share (as adjusted for subsequent stock dividends, splits, combinations or similar events), each share of Series B Preferred Stock shall automatically be converted into such number of fully paid and nonassessable shares of
Common Stock as is determined by dividing (1) the Series B Issue Price plus the amount of all accrued and unpaid Cumulative Dividends and any other accrued but unpaid dividends on such Series B Preferred Stock by (2) the Conversion Price
at the time in effect for the Series B Preferred Stock. 
 (ii) Upon the occurrence of the events specified in
subsection (i) in Section 4(f) of this Article IV.B, the outstanding shares of Series B Preferred Stock shall be converted automatically into fully paid and nonassessable shares of Common Stock as set forth above
without any further action by the holders of such shares and whether or not the certificates representing such shares are surrendered to the Corporation or its transfer agent; provided, however, that the Corporation shall not be obligated to issue
certificates evidencing the shares of Common Stock issuable upon such conversion unless the certificates evidencing such shares of Series B Preferred Stock are either delivered to the Corporation or its transfer agent as provided below, or the
holder notifies the Corporation or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement reasonably satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in
connection with the loss, theft or destruction of such certificates. Upon the occurrence of such automatic conversion of the Series B Preferred Stock, (x) the Corporation shall notify (the “Automatic Conversion Notice”)
each holder of Series B Preferred Stock who is shown to be such a holder on the books of the Corporation as of the time immediately prior to such conversion and (y) the holders of Series B Preferred Stock shall surrender the certificates
representing such shares at the office of the Corporation or any transfer agent for the Series B Preferred Stock, which shall be designated in the Automatic Conversion Notice. Thereupon, there shall be issued and delivered to such holder promptly at
such office and in its name as shown on such surrendered certificate or certificates, a certificate or certificates representing the number of shares of Common Stock into which the shares of Series B Preferred Stock surrendered were convertible on
the date on which such automatic conversion occurred. 
 14.5 General Voting Rights. 
 (a) General. Except as otherwise provided herein or required by law, each holder of Series B Preferred Stock shall be entitled to the
number of votes equal to the number of shares of Common Stock into which the shares of Series B Preferred Stock so held could be converted (subject

  

 10 

 
to the limitations on conversion contained in Section 5(c) of this Article IV.B.) at the record date for determination of the stockholders entitled to vote, or, if no such record
date is established, at the date such vote is taken or any written consent of stockholders is first executed and delivered. If the application of Section 5(c) of this Article IV.B. hereof shall cause a limitation in the number of
shares of Common Stock otherwise issuable into which the shares of Series B Preferred Stock are then convertible, then the votes associated with the number of shares of Common Stock that can be issued upon conversion shall be proportionately
allocated to the shares of Series B Preferred Stock then outstanding. Except as required by law or otherwise set forth herein, all shares of Series B Preferred Stock and all shares of Common Stock shall vote together as a single class on an
as-converted basis (subject to the limitations on conversion contained in Section 5(c) of this Article IV.B.). The Series B Preferred Stock shall not be entitled to cumulative voting except as required by law. 
 (b) No Violation of NASD Rule 4351. Notwithstanding any other provision of this Section 5, in the event that the
Corporation determines, after consultation with NASDAQ or any other securities exchange on which the Corporation’s Common Stock is then listed or traded (after full process, including any appeal process available to the Corporation) that the
voting provisions set forth in this Section 5 violate or conflict with Rule 4351 of the National Association of Securities Dealers, Inc. (the “NASD”), or any successor or similar rule, or the rules or
regulations of any such securities exchange on which the Common Stock is then listed or traded, then the manner of voting and/or number of votes to which each share of Series B Preferred Stock is entitled shall be modified and/or reduced to the
extent required to comply with such rule. 
 (c) Minimum Conversion Price Regarding Voting. Notwithstanding any contrary
or inconsistent provision hereof, for the purpose only of determining the number of votes each share of Series B Preferred Stock shall be entitled to vote pursuant to this Section 5, the Conversion Price on the record date for the taking
of any vote (or, if no such record date is established, at the date such vote is taken or any written consent of stockholders is solicited) shall not in any case be deemed less than an amount equal to the Closing Price of the Common Stock on the
Initial Series B Issue Date (as adjusted to reflect any stock dividends, distributions, combinations, reclassifications and other similar transactions effected by the Corporation in respect to its Common Stock). 
 14.6 Protective Provisions. Once at least 1,666,667 shares of Series B Preferred Stock are issued (as adjusted for stock splits,
stock dividends, recapitalizations and the like applicable to the Series B Preferred Stock), then as long as at least 500,000 shares of Series B Preferred Stock remain outstanding, the Corporation shall not (and shall cause its subsidiaries not to),
without first obtaining the approval of the holders of a majority of the then-outstanding shares of Series B Preferred Stock: 
 (a) authorize or issue any new class or series of capital stock, or reclassify any existing class or series of capital stock, if the effect of such action would result in a class or series of capital stock having a preference with respect
to dividends, liquidation or redemption rights senior to the Series B Preferred Stock; 
 (b) amend the Corporation’s
Certificate of Incorporation, bylaws or this Certificate of Designations in a manner that adversely affects the rights, preferences and privileges of the Series B Preferred Stock, or increase or decrease the total number of authorized shares of
Series B Preferred Stock; 
  

 11 

 (c) declare or pay any dividend upon or redeem any of the capital stock of the Corporation
that is junior to or pari passu with the Series B Preferred Stock as to liquidation or dividend payments; 
 (d) sell or
otherwise dispose of all or substantially all of the assets of the Corporation, merge or consolidate with any entity (except for the purpose of a change of domicile of the Corporation) or effect a transaction in which more than 50% of the voting
power in the Corporation is disposed of; 
 (e) create, incur, assume or suffer to exist any indebtedness for borrowed money
(including capitalized lease financings) or issue any guarantees, or mortgage, encumber, create, incur, or suffer to exist liens related thereto, other than (a) indebtedness and liens which are permitted under Sections 8.1 and 8.2 of that
certain Credit Agreement dated as of January 10, 2008, by and among the Corporation, as borrower, the lenders from time to time party thereto, the letter of credit issuers from time to time party thereto, Churchill Financial LLC, as
administrative agent, and Ableco Finance LLC, as collateral agent (the “First Lien Credit Agreement”), and (b) any debt or other extensions of credit by the lenders or their affiliates under the First Lien Credit Agreement or
pursuant to any extensions, amendments, modifications, or refinancings thereof; 
 (f) create, form or invest in any entity in
which the Corporation or any subsidiary of the Corporation would have more than a 5% ownership interest; 
 (g) increase the
size of the Board of Directors of the Corporation; or 
 (h) reorganize, dissolve, liquidate or otherwise wind up the
Corporation. 
 14.7 Miscellaneous. Shares of Series B Preferred Stock issued and redeemed or otherwise reacquired by the
Corporation shall be retired promptly after the reacquisition thereof and, upon compliance with the applicable provisions of Delaware law, shall have the status of authorized but unissued shares of preferred stock of the Corporation. 
 [SIGNATURE PAGE FOLLOWS] 
  

 12 

 IN WITNESS WHEREOF, Purple Communications, Inc. has caused this Certificate of Designations
to be signed and attested by the undersigned this 14th day of December, 2009. 
  

			
	PURPLE COMMUNICATIONS, INC.
		
	By:	 	  

	Name:	 	Dan Luis
	Title:	 	Chief Executive Officer

 Exhibit A-2 
 Form of Certificate of Amendment 
 CERTIFICATE OF AMENDMENT 
 OF 
 FOURTH
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 
 OF 
 PURPLE COMMUNICATIONS, INC., 
 a Delaware corporation

 (pursuant to Section 242 of the Delaware General Corporation Law) 
 Purple Communications, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the
“Corporation”), through its duly authorized officers and by authority of its Board of Directors does hereby certify: 
 FIRST: That in accordance with the provisions of Section 242 of the General Corporation Law, the Board of Directors of the Corporation duly adopted resolutions setting forth a proposed amendment to the Fourth Amended and Restated
Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that said amendment be submitted to the stockholders of the Corporation for consideration thereof. The resolution setting forth the proposed
amendment is as follows: 
 RESOLVED, that Section A of Article IV of the Fourth Amended and Restated Certificate of
Incorporation is hereby amended and restated to read in full as follows: 
 “ARTICLE IV 
 A. Classes of Stock. The Corporation is authorized to issue two classes of capital stock designated “Common Stock” and
“Preferred Stock”, respectively. The total number of shares which the Corporation is authorized to issue is Four Hundred Twenty Million (420,000,000), of which Four Hundred Million (400,000,000) shares shall be Common Stock, par value
$0.01 per share, and Twenty Million (20,000,000) shares shall be Preferred Stock, par value $0.01 per share.” 
 SECOND: That thereafter, the holders of the necessary number of shares of capital stock of the Corporation gave their written consent in favor of the foregoing amendment in accordance with the provisions of Section 228 of the Delaware
General Corporation Law. 
 THIRD: That the amendment of the Fourth Amended and Restated Certificate of Incorporation herein
certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, Purple Communications, Inc. has caused this Certificate of Amendment to
be signed by Michael J. Pendergast, its duly authorized General Counsel and Secretary, this      day of         , 2010. 
  

	
	  

	Michael J. Pendergast,
	General Counsel and Secretary

  

 15 

 Exhibit B 
 Form of Officer’s Certificate 
 PURPLE COMMUNICATIONS, INC. 

COMPLIANCE CERTIFICATE 
 December     , 2009 
 The undersigned, John R.
Ferron, President and Chief Financial Officer of Purple Communications, Inc., a Delaware corporation (the “Company”), pursuant to Section 5.3 of that certain Series B Preferred Stock Purchase Agreement, dated as of the date
hereof (the “Purchase Agreement”), by and among the Company and each of the Investors listed on Schedule A attached thereto, does hereby certify to the Investors on behalf of the Company as follows: 
  

	 	1.	The representations and warranties of the Company set forth in the Purchase Agreement are true and correct in all respects (without giving effect to any
“materiality,” “Material Adverse Effect” or similar qualifiers contained in any such representations and warranties, other than any qualifiers contained in any representation or warranty requiring disclosure in the Disclosure
Letter of a list of items qualified as to materiality) as of the date hereof as though made on and as of the date hereof (unless any such representation or warranty is made only as of a specific date, in which event such representation and warranty
shall be so true and correct as of such specified date), except where the failure of any such representations and warranties to be so true and correct, in the aggregate, has not had, and would not reasonably be expected to have, a Material Adverse
Effect. 

  

	 	2.	The Company has performed and complied in all material respects with all agreements, obligations and conditions contained in the Purchase Agreement that are required to
be performed or complied with by the Company on or before the date hereof. 

 Unless otherwise set forth herein,
all capitalized terms in this Certificate shall have the respective meanings ascribed to them in the Purchase Agreement. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the undersigned has executed this Compliance Certificate as of the date
first set forth above. 
  

	
	Purple Communications, Inc.
	
	  

	John R. Ferron
	President and Chief Financial Officer

 Exhibit C 
 Form of Legal Opinion 
 1. The Company is a corporation validly existing and in
good standing under the laws of the State of Delaware. The Company is qualified to do business as a foreign corporation in the State of New Jersey and the State of California. 
 2. The Company has the corporate power and corporate authority necessary, under the General Corporation Law of the State of Delaware, its
certificate of incorporation, and the bylaws, to own its properties and assets and to conduct its business as, to our current actual knowledge, it is presently conducted, and to enter into each of the Transaction Documents and perform its
obligations thereunder. 
 3. The Transaction Documents have been duly authorized by all necessary corporate action on the part
of the Company and have been duly executed and delivered by the Company. 
 4. Each of the Transaction Documents is a valid and
binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability thereof may be subject to or limited by (a) bankruptcy, insolvency, reorganization, arrangement, moratorium, or other
similar laws, now or hereafter in effect, relating to or affecting the rights of creditors, and (b) general equitable principles, regardless of whether the issue of enforceability is considered in a proceeding in equity or at law. 

5. The shares of Series B Preferred Stock to be issued to the Investor at the Closing have been duly authorized and, when issued and paid
for in accordance with the terms of the Purchase Agreement, will be validly issued, fully paid and nonassessable. Subject to the approval by the Company’s stockholders and the filing of the Certificate of Amendment with the Delaware Secretary
of State, the Conversion Shares and the Warrant Shares have been duly and validly reserved for issuance and, when and if issued upon conversion in accordance with the Certificate, as amended by the Certificate of Amendment, in the case of the
Conversion Shares, and when and if issued upon exercise of the Warrant in the case of the Warrant Shares, will be validly issued, fully paid and nonassessable. 
 6. Based in part upon the representations of the Purchaser contained in the Purchase Agreement, the offer, sale, issuance and delivery of the shares of Series B Preferred Stock and the Warrant, and the
issuance of the Conversion Shares and Warrant Shares issuable upon conversion or exercise thereof, under the circumstances contemplated by the Purchase Agreement is exempt from the registration requirements of the Securities Act of 1933, as amended.

 7. Except as disclosed in the Transaction Documents, the exhibits and schedules delivered in connection therewith, or the
Disclosure Letter, and subject to the approval by the Company’s stockholders of the Certificate of Amendment and the filing of the Certificate of Amendment with the Delaware Secretary of State, the execution and delivery of the Transaction
Documents and the performance by the Company of their respective terms will not breach or result in a violation of (a) the Company’s Certificate of incorporation or Bylaws, (b) applicable federal or California law, or (c) any
judgment, order or decree of any domestic court or arbitrator, known to us, to which the Company is a party or is subject. 

 8. Except as disclosed in the Transaction Documents, the exhibits and schedules delivered in
connection therewith, or the Disclosure Letter, no consent, approval or authorization of, or designation, declaration or filing with, any governmental authority is required in connection with the valid execution, delivery and performance by the
Company of the Transaction Documents, other than (i) such consents, approvals, authorizations, designations, declarations or filings as have been made or obtained on or before the date hereof or which are not required to be made or obtained
until after the date hereof and (ii) the approval by the stockholders of the Company of the Certificate of Amendment and the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware. 

 Exhibit D-1 
 Form of Series A Stockholder Consent 
 ACTION BY WRITTEN CONSENT OF

 THE SERIES A PREFERRED STOCKHOLDERS OF 
 PURPLE COMMUNICATIONS, INC., 
 a Delaware corporation 
 December     , 2009 
 The undersigned, constituting the holders of          shares of Series A Preferred Stock of Purple Communications, Inc., a Delaware corporation (the
“Corporation”), in accordance with the authority contained in Section 228 of the Delaware General Corporation Law and the Bylaws of the Corporation, hereby consent to the adoption of the following recitals and resolutions:

 APPROVAL OF AMENDMENT OF CERTIFICATE OF INCORPORATION 
 WHEREAS, the number of shares of Common Stock, par value $0.01 per share (“Common Stock”), this Corporation
is authorized to issue is insufficient to permit (i) the conversion of the shares of Series B Preferred Stock of the Corporation, (ii) the exercise of the Common Stock Warrants of the Corporation and (iii) the adjustment to the
Conversion Price of Series A Preferred Stock (as defined in the Corporation’s Fourth Amended and Restated Certificate of Incorporation) as a result of the issuance of the Series B Preferred Stock; 
 WHEREAS, it has been proposed by the Board of Directors that the form of Certificate of Amendment to the Corporation’s
Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), in the form attached hereto as Exhibit A and incorporated herein by reference, which shall increase the total authorized number of
shares of the Corporation to Four Hundred Twenty Million (420,000,000) shares, increase the total authorized number of shares of Common Stock to Four Hundred Million (400,000,000) and increase the total authorized number of shares of
preferred stock, par value $0.01 per share, to Twenty Million (20,000,000), be approved by the stockholders of the Corporation; and 
 WHEREAS, it is deemed to be advisable and in the best interests of the Corporation and its stockholders to approve and adopt the Certificate of Amendment, which shall become effective upon filing with the
Delaware Secretary of State. 
 NOW, THEREFORE, BE IT RESOLVED, that the amendment of the Corporation’s
Fourth Amended and Restated Certificate of Incorporation, and the form, terms and provisions of the Certificate of Amendment and any other documents and agreements to be executed and delivered in connection therewith, copies of which have been
submitted to and considered by the undersigned, be, and the same hereby are, approved, adopted and ratified; 

 RESOLVED FURTHER, that the officers of the Corporation be, and each of them
hereby is, authorized and directed on behalf of the Corporation and in its name to execute the Certificate of Amendment, with such modifications, amendments or insertions thereto as may be approved by the officer or officers executing the same, such
approval to be conclusively evidenced by the execution thereof, and to cause the Certificate of Amendment to be filed with the Delaware Secretary of State. 
 GENERAL AUTHORITY 
 RESOLVED FURTHER, that the
officers of the Corporation be, and each of them hereby is, authorized, directed and empowered on behalf of the Corporation and in its name, at any time and from time to time to do and perform any and all acts or things, including, without
limitation, the execution and delivery of any and all further agreements, documents, instruments or papers of whatever kind or nature, which such officers or any of them may consider necessary or desirable to effect the intent of any and all of the
foregoing resolutions; and the performance of such other acts and things by any of such officers shall evidence conclusively and for all purposes that such officer or officers considered the same to be necessary or desirable as aforesaid and that
such act or thing so done or performed was hereby authorized; and that all such acts or things heretofore performed by the officers of the Corporation are hereby ratified and approved; and 
 RESOLVED FURTHER, that these resolutions adopted by the undersigned may be executed in two or more counterparts, and by
telefax transmission, and each such counterpart shall be deemed an original, and all of which, when taken together, shall constitute but one and the same instrument. 

 Exhibit D-2 
 Form of Series B Stockholder Consent 
 ACTION BY WRITTEN CONSENT OF

 THE SERIES B PREFERRED STOCKHOLDERS OF 
 PURPLE COMMUNICATIONS, INC., 
 a Delaware corporation 
 December __, 2009 
 The undersigned, constituting the holders of          shares of Series B Preferred Stock of Purple Communications, Inc., a Delaware corporation (the “Corporation”), in
accordance with the authority contained in Section 228 of the Delaware General Corporation Law and the Bylaws of the Corporation, hereby consent to the adoption of the following recitals and resolutions: 
 APPROVAL OF AMENDMENT OF CERTIFICATE OF INCORPORATION 
 WHEREAS, the number of shares of Common Stock, par value $0.01 per share (“Common Stock”), this Corporation
is authorized to issue is insufficient to permit (i) the conversion of the shares of Series B Preferred Stock of the Corporation, (ii) the exercise of the Common Stock Warrants of the Corporation and (iii) the adjustment to the
Conversion Price of Series A Preferred Stock (as defined in the Corporation’s Fourth Amended and Restated Certificate of Incorporation) as a result of the issuance of the Series B Preferred Stock; 
 WHEREAS, it has been proposed by the Board of Directors that the form of Certificate of Amendment to the Corporation’s
Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), in the form attached hereto as Exhibit A and incorporated herein by reference, which shall increase the total authorized number of
shares of the Corporation to Four Hundred Twenty Million (420,000,000) shares, increase the total authorized number of shares of Common Stock to Four Hundred Million (400,000,000) and increase the total authorized number of shares of
preferred stock, par value $0.01 per share, to Twenty Million (20,000,000), be approved by the stockholders of the Corporation; and 
 WHEREAS, it is deemed to be advisable and in the best interests of the Corporation and its stockholders to approve and adopt the Certificate of Amendment, which shall become effective upon filing with the
Delaware Secretary of State. 
 NOW, THEREFORE, BE IT RESOLVED, that the amendment of the Corporation’s
Fourth Amended and Restated Certificate of Incorporation, and the form, terms and provisions of the Certificate of Amendment and any other documents and agreements to be executed and delivered in connection therewith, copies of which have been
submitted to and considered by the undersigned, be, and the same hereby are, approved, adopted and ratified; 

 RESOLVED FURTHER, that the officers of the Corporation be, and each of them
hereby is, authorized and directed on behalf of the Corporation and in its name to execute the Certificate of Amendment, with such modifications, amendments or insertions thereto as may be approved by the officer or officers executing the same, such
approval to be conclusively evidenced by the execution thereof, and to cause the Certificate of Amendment to be filed with the Delaware Secretary of State. 
 GENERAL AUTHORITY 
 RESOLVED FURTHER, that the
officers of the Corporation be, and each of them hereby is, authorized, directed and empowered on behalf of the Corporation and in its name, at any time and from time to time to do and perform any and all acts or things, including, without
limitation, the execution and delivery of any and all further agreements, documents, instruments or papers of whatever kind or nature, which such officers or any of them may consider necessary or desirable to effect the intent of any and all of the
foregoing resolutions; and the performance of such other acts and things by any of such officers shall evidence conclusively and for all purposes that such officer or officers considered the same to be necessary or desirable as aforesaid and that
such act or thing so done or performed was hereby authorized; and that all such acts or things heretofore performed by the officers of the Corporation are hereby ratified and approved; and 
 RESOLVED FURTHER, that these resolutions adopted by the undersigned may be executed in two or more counterparts, and by
telefax transmission, and each such counterpart shall be deemed an original, and all of which, when taken together, shall constitute but one and the same instrument. 

 Exhibit D-3 
 Form of As-Converted Common Stockholder Consent 
 ACTION BY WRITTEN CONSENT OF

 THE COMMON STOCKHOLDERS OF 
 PURPLE COMMUNICATIONS, INC., 
 a Delaware corporation 
 December     , 2009 
 The undersigned, constituting the holders of          shares of common stock of Purple Communications, Inc., a Delaware corporation (the
“Corporation”), in accordance with the authority contained in Section 228 of the Delaware General Corporation Law and the Bylaws of the Corporation, hereby consent to the adoption of the following recitals and resolutions:

 APPROVAL OF AMENDMENT OF CERTIFICATE OF INCORPORATION 
 WHEREAS, the number of shares of Common Stock, par value $0.01 per share (“Common Stock”), this Corporation
is authorized to issue is insufficient to permit (i) the conversion of the shares of Series B Preferred Stock of the Corporation, (ii) the exercise of the Common Stock Warrants of the Corporation and (iii) the adjustment to the
Conversion Price of Series A Preferred Stock (as defined in the Corporation’s Fourth Amended and Restated Certificate of Incorporation) as a result of the issuance of the Series B Preferred Stock; 
 WHEREAS, it has been proposed by the Board of Directors that the form of Certificate of Amendment to the Corporation’s
Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), in the form attached hereto as Exhibit A and incorporated herein by reference, which shall increase the total authorized number of
shares of the Corporation to Four Hundred Twenty Million (420,000,000) shares, increase the total authorized number of shares of Common Stock to Four Hundred Million (400,000,000) and increase the total authorized number of shares of
preferred stock, par value $0.01 per share, to Twenty Million (20,000,000), be approved by the stockholders of the Corporation; and 
 WHEREAS, it is deemed to be advisable and in the best interests of the Corporation and its stockholders to approve and adopt the Certificate of Amendment, which shall become effective upon filing with the
Delaware Secretary of State. 
 NOW, THEREFORE, BE IT RESOLVED, that the amendment of the Corporation’s
Fourth Amended and Restated Certificate of Incorporation, and the form, terms and provisions of the Certificate of Amendment and any other documents and agreements to be executed and delivered in connection therewith, copies of which have been
submitted to and considered by the undersigned, be, and the same hereby are, approved, adopted and ratified; 
  

 A-1 

 RESOLVED FURTHER, that the officers of the Corporation be, and each of them
hereby is, authorized and directed on behalf of the Corporation and in its name to execute the Certificate of Amendment, with such modifications, amendments or insertions thereto as may be approved by the officer or officers executing the same, such
approval to be conclusively evidenced by the execution thereof, and to cause the Certificate of Amendment to be filed with the Delaware Secretary of State. 
 GENERAL AUTHORITY 
 RESOLVED FURTHER, that the
officers of the Corporation be, and each of them hereby is, authorized, directed and empowered on behalf of the Corporation and in its name, at any time and from time to time to do and perform any and all acts or things, including, without
limitation, the execution and delivery of any and all further agreements, documents, instruments or papers of whatever kind or nature, which such officers or any of them may consider necessary or desirable to effect the intent of any and all of the
foregoing resolutions; and the performance of such other acts and things by any of such officers shall evidence conclusively and for all purposes that such officer or officers considered the same to be necessary or desirable as aforesaid and that
such act or thing so done or performed was hereby authorized; and that all such acts or things heretofore performed by the officers of the Corporation are hereby ratified and approved; and 
 RESOLVED FURTHER, that these resolutions adopted by the undersigned may be executed in two or more counterparts, and by
telefax transmission, and each such counterpart shall be deemed an original, and all of which, when taken together, shall constitute but one and the same instrument.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]